PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19016842-5	2008	We show that harmine not only inhibits the protein-serine/threonine kinase activity of mature DYRK1A, but also its autophosphorylation on tyrosine during translation, indicating that harmine prevents formation of the active enzyme.	Harmine	183-190	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	94-100
18938227-6	2008	Phosphorylation of SEPT4 by DYRK1A was inhibited by harmine, which has recently been identified as the most specific inhibitor of DYRK1A.	Harmine	52-59	septin 4	Homo sapiens	19-24
18938227-6	2008	Phosphorylation of SEPT4 by DYRK1A was inhibited by harmine, which has recently been identified as the most specific inhibitor of DYRK1A.	Harmine	52-59	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	28-34
18938227-6	2008	Phosphorylation of SEPT4 by DYRK1A was inhibited by harmine, which has recently been identified as the most specific inhibitor of DYRK1A.	Harmine	52-59	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	130-136
19016842-0	2008	DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine.	Harmine	98-105	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	0-6
17039880-0	2006	[Harmine induces apoptosis in human SGC-7901 cells].	Harmine	1-8	sarcoglycan beta	Homo sapiens	36-39
19016842-0	2008	DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine.	Harmine	98-105	caspase 9	Homo sapiens	22-31
19016842-4	2008	DYRK1A-dependent phosphorylation of Thr125 is also blocked by harmine, confirming the use of this beta-carboline alkaloid as a potent inhibitor of DYRK1A in cells.	Harmine	62-69	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	0-6
19016842-4	2008	DYRK1A-dependent phosphorylation of Thr125 is also blocked by harmine, confirming the use of this beta-carboline alkaloid as a potent inhibitor of DYRK1A in cells.	Harmine	62-69	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	147-153
19016842-5	2008	We show that harmine not only inhibits the protein-serine/threonine kinase activity of mature DYRK1A, but also its autophosphorylation on tyrosine during translation, indicating that harmine prevents formation of the active enzyme.	Harmine	13-20	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	94-100
17850214-3	2007	We have also identified harmine as a potent and specific inhibitor of DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A) in vitro.	Harmine	24-31	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	70-76
17850214-3	2007	We have also identified harmine as a potent and specific inhibitor of DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A) in vitro.	Harmine	24-31	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	78-143
18562627-1	2008	We previously identified the small molecule harmine as a regulator of peroxisome proliferator activated-receptor gamma (PPARgamma) and adipocyte differentiation.	Harmine	44-51	peroxisome proliferator activated receptor gamma	Mus musculus	70-118
18562627-1	2008	We previously identified the small molecule harmine as a regulator of peroxisome proliferator activated-receptor gamma (PPARgamma) and adipocyte differentiation.	Harmine	44-51	peroxisome proliferator activated receptor gamma	Mus musculus	120-129
18562627-3	2008	Inhibitor of DNA biding 2 (Id2) was identified as a gene rapidly induced by harmine but not by PPARgamma agonists.	Harmine	76-83	inhibitor of DNA binding 2	Mus musculus	0-25
18562627-3	2008	Inhibitor of DNA biding 2 (Id2) was identified as a gene rapidly induced by harmine but not by PPARgamma agonists.	Harmine	76-83	inhibitor of DNA binding 2	Mus musculus	27-30
17488638-0	2007	The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression.	Harmine	19-26	peroxisome proliferator activated receptor gamma	Mus musculus	78-87
17488638-3	2007	This molecule, harmine, is not a ligand for the receptor; rather, it acts as a cell-type-specific regulator of PPARgamma expression.	Harmine	15-22	peroxisome proliferator activated receptor gamma	Mus musculus	111-120
17488638-4	2007	Administration of harmine to diabetic mice mimics the effects of PPARgamma ligands on adipocyte gene expression and insulin sensitivity.	Harmine	18-25	peroxisome proliferator activated receptor gamma	Mus musculus	65-74
17488638-6	2007	Molecular studies indicate that harmine controls PPARgamma expression through inhibition of the Wnt signaling pathway.	Harmine	32-39	peroxisome proliferator activated receptor gamma	Mus musculus	49-58
17088501-8	2006	MAIN OUTCOME MEASURE: Harmine labeled with carbon 11, a radioligand selective for MAO-A and positron emission tomography, was used to measure MAO-A DVS (specific distribution volume), an index of MAO-A density, in different brain regions (prefrontal cortex, anterior cingulate cortex, posterior cingulate cortex, caudate, putamen, thalamus, anterior temporal cortex, midbrain, hippocampus, and parahippocampus).	Harmine	22-29	monoamine oxidase A	Homo sapiens	82-87
17088501-8	2006	MAIN OUTCOME MEASURE: Harmine labeled with carbon 11, a radioligand selective for MAO-A and positron emission tomography, was used to measure MAO-A DVS (specific distribution volume), an index of MAO-A density, in different brain regions (prefrontal cortex, anterior cingulate cortex, posterior cingulate cortex, caudate, putamen, thalamus, anterior temporal cortex, midbrain, hippocampus, and parahippocampus).	Harmine	22-29	monoamine oxidase A	Homo sapiens	142-147
17088501-8	2006	MAIN OUTCOME MEASURE: Harmine labeled with carbon 11, a radioligand selective for MAO-A and positron emission tomography, was used to measure MAO-A DVS (specific distribution volume), an index of MAO-A density, in different brain regions (prefrontal cortex, anterior cingulate cortex, posterior cingulate cortex, caudate, putamen, thalamus, anterior temporal cortex, midbrain, hippocampus, and parahippocampus).	Harmine	22-29	monoamine oxidase A	Homo sapiens	142-147
17039880-1	2006	OBJECTIVE: [corrected] To investigate the effect of apoptosis induced in human SGC-7901 cells by Harmine.	Harmine	97-104	sarcoglycan beta	Homo sapiens	79-82
17039880-2	2006	METHODS: The effect of Harmine on human SGC-7901 cell survival and apoptosis was determined by MTT assay, light microscopy and flow cytometry.	Harmine	23-30	sarcoglycan beta	Homo sapiens	40-43
16079787-0	2006	Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain.	Harmine	53-60	monoamine oxidase A	Homo sapiens	72-91
16079787-1	2006	This article describes the kinetic modeling of [(11)C]-harmine binding to monoamine oxidase A (MAO-A) binding sites in the human brain using positron emission tomography (PET).	Harmine	55-62	monoamine oxidase A	Homo sapiens	74-93
16079787-1	2006	This article describes the kinetic modeling of [(11)C]-harmine binding to monoamine oxidase A (MAO-A) binding sites in the human brain using positron emission tomography (PET).	Harmine	55-62	monoamine oxidase A	Homo sapiens	95-100
16079787-8	2006	Moclobemide treatment leads to a 64% to 79% MAO-A blockade across brain regions, a result that supports the specificity of [(11)C]-harmine binding to MAO-A.	Harmine	131-138	monoamine oxidase A	Homo sapiens	150-155
12900293-6	2003	RESULTS: The MAO-A-ligand Harmine expressed specific in vitro binding of 87 +/-21% for MGC and 125 +/- 50% for EPT, compared to reference tissue (rat brain, 100%).	Harmine	26-33	monoamine oxidase A	Rattus norvegicus	13-18
16149329-1	2005	Harmine, a major alkaloid in ayahuasca (hoasca), is a selective and reversible inhibitor of the enzyme monoamine oxidase-A (MAO-A).	Harmine	0-7	monoamine oxidase A	Homo sapiens	103-122
16149329-1	2005	Harmine, a major alkaloid in ayahuasca (hoasca), is a selective and reversible inhibitor of the enzyme monoamine oxidase-A (MAO-A).	Harmine	0-7	monoamine oxidase A	Homo sapiens	124-129
16149329-2	2005	It is also a selective inhibitor of the human cytochrome P450 isozyme 2D6 (CYP 2D6), which metabolizes harmine to a more hydrophilic derivative for eventual excretion.	Harmine	103-110	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	46-73
16149329-2	2005	It is also a selective inhibitor of the human cytochrome P450 isozyme 2D6 (CYP 2D6), which metabolizes harmine to a more hydrophilic derivative for eventual excretion.	Harmine	103-110	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	75-82
16149329-4	2005	This report broadly describes two subgroups of CYP 2D6 phenotypes--i.e., fast and slow metabolizers of harmine-in 14 experienced male members of the Uniao do Vegetal (UDV) who received a standardized dosage of hoasca.	Harmine	103-110	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	47-54
15047157-2	2004	In the present study, harmine was identified from a collection of herbal compounds to be a specific inhibitor of Cdk1/cyclin B, Cdk2/cyclin A, and Cdk5/p25 with IC50 values at low micromoles.	Harmine	22-29	cyclin dependent kinase 1	Homo sapiens	113-117
15047157-2	2004	In the present study, harmine was identified from a collection of herbal compounds to be a specific inhibitor of Cdk1/cyclin B, Cdk2/cyclin A, and Cdk5/p25 with IC50 values at low micromoles.	Harmine	22-29	cyclin dependent kinase 2	Homo sapiens	128-132
15047157-2	2004	In the present study, harmine was identified from a collection of herbal compounds to be a specific inhibitor of Cdk1/cyclin B, Cdk2/cyclin A, and Cdk5/p25 with IC50 values at low micromoles.	Harmine	22-29	cyclin A2	Homo sapiens	133-141
15047157-2	2004	In the present study, harmine was identified from a collection of herbal compounds to be a specific inhibitor of Cdk1/cyclin B, Cdk2/cyclin A, and Cdk5/p25 with IC50 values at low micromoles.	Harmine	22-29	cyclin dependent kinase 5	Homo sapiens	147-151
15047157-2	2004	In the present study, harmine was identified from a collection of herbal compounds to be a specific inhibitor of Cdk1/cyclin B, Cdk2/cyclin A, and Cdk5/p25 with IC50 values at low micromoles.	Harmine	22-29	cyclin dependent kinase 5 regulatory subunit 1	Homo sapiens	152-155
15047157-4	2004	The CDK inhibition by harmine is competitive with ATP-Mg2+, suggesting that it binds to the ATP-Mg2+-binding pocket of CDKs.	Harmine	22-29	cyclin dependent kinase 1	Homo sapiens	119-123
15047157-7	2004	Taken together, harmine is a selective inhibitor of CDKs and cell proliferation.	Harmine	16-23	cyclin dependent kinase 1	Homo sapiens	52-56
12649384-2	2003	Cytochromes P450 1A1 (18.5), 1A2 (20), and 2D6 (100) catalyzed the O-demethylation of harmaline, and CYP1A1 (98.5), CYP1A2 (35), CYP2C9 (16), CYP2C19 (30), and CYP2D6 (115) catalyzed that of harmine (relative activities).	Harmine	191-198	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	101-107
12649384-2	2003	Cytochromes P450 1A1 (18.5), 1A2 (20), and 2D6 (100) catalyzed the O-demethylation of harmaline, and CYP1A1 (98.5), CYP1A2 (35), CYP2C9 (16), CYP2C19 (30), and CYP2D6 (115) catalyzed that of harmine (relative activities).	Harmine	191-198	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	116-122
12649384-6	2003	Values for harmine were: CYP1A1, 45.2 and 52.2; CYP1A2, 9.2 and 14.7; CYP2C9, 11.9 and 117; CYP2C19, 21.4 and 121; and CYP2D6, 29.7 and 7.4.	Harmine	11-18	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	25-31
12649384-6	2003	Values for harmine were: CYP1A1, 45.2 and 52.2; CYP1A2, 9.2 and 14.7; CYP2C9, 11.9 and 117; CYP2C19, 21.4 and 121; and CYP2D6, 29.7 and 7.4.	Harmine	11-18	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	48-54
12649384-6	2003	Values for harmine were: CYP1A1, 45.2 and 52.2; CYP1A2, 9.2 and 14.7; CYP2C9, 11.9 and 117; CYP2C19, 21.4 and 121; and CYP2D6, 29.7 and 7.4.	Harmine	11-18	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	70-76
12649384-6	2003	Values for harmine were: CYP1A1, 45.2 and 52.2; CYP1A2, 9.2 and 14.7; CYP2C9, 11.9 and 117; CYP2C19, 21.4 and 121; and CYP2D6, 29.7 and 7.4.	Harmine	11-18	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	119-125
12649384-7	2003	Inhibition studies using monoclonal antibodies confirmed that CYP1A2 and CYP2D6 were the major isozymes contributing to both harmaline (20% and 50%, respectively) and harmine (20% and 30%) O-demethylations in pooled HLMs.	Harmine	167-174	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	62-68
12649384-7	2003	Inhibition studies using monoclonal antibodies confirmed that CYP1A2 and CYP2D6 were the major isozymes contributing to both harmaline (20% and 50%, respectively) and harmine (20% and 30%) O-demethylations in pooled HLMs.	Harmine	167-174	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	73-79
12649384-10	2003	These findings suggest a role for polymorphic CYP2D6 in the pharmacology and toxicology of harmine and harmaline.	Harmine	91-98	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	46-52
12445480-5	2002	The inhibitors, D-amphetamine, harmine, tetrindole, and befloxatone all induce similar (but not identical) changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site.	Harmine	31-38	monoamine oxidase A	Homo sapiens	134-139
12445480-6	2002	D-Amphetamine, harmine, and tetrindole stabilise the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of these inhibitor-MAO A complexes has been observed.	Harmine	15-22	monoamine oxidase A	Homo sapiens	97-102
11890933-5	2002	Mutants defective in excision-resynthesis repair (rad3 and rad1), in error-prone repair (rad6) and in recombinational repair (rad52) showed enhanced sensitivity to harmine and harman, but the ranking of sensitivities was different for the two alkaloids.	Harmine	164-171	TFIIH/NER complex ATP-dependent 5'-3' DNA helicase subunit RAD3	Saccharomyces cerevisiae S288C	50-54
11890933-5	2002	Mutants defective in excision-resynthesis repair (rad3 and rad1), in error-prone repair (rad6) and in recombinational repair (rad52) showed enhanced sensitivity to harmine and harman, but the ranking of sensitivities was different for the two alkaloids.	Harmine	164-171	ssDNA endodeoxyribonuclease RAD1	Saccharomyces cerevisiae S288C	59-63
11890933-5	2002	Mutants defective in excision-resynthesis repair (rad3 and rad1), in error-prone repair (rad6) and in recombinational repair (rad52) showed enhanced sensitivity to harmine and harman, but the ranking of sensitivities was different for the two alkaloids.	Harmine	164-171	E2 ubiquitin-conjugating protein RAD6	Saccharomyces cerevisiae S288C	89-93
11797076-10	2001	Taken together, these results indicate that harmine affects the brain dopamine system probably by acting as a MAO-A inhibitor and not as an inverse agonist for the benzodiazepine receptors.	Harmine	44-51	monoamine oxidase A	Rattus norvegicus	110-115
9503561-4	1997	MAO-A preferentially deaminates serotonin (5HT) and is selectively inhibited by harmine and clorgyline, while MAO-B preferentially deaminates phenethylamine and benzylamine, and is selectively inhibited by (-)deprenyl as well as low concentrations of pargyline.	Harmine	80-87	monoamine oxidase A	Homo sapiens	0-5
10404423-2	1999	Such beverages are characterized by the presence of these three harmala alkaloids, where harmine and harmaline reversibly inhibit monoamine oxidase A (MAO-A) while tetrahydroharmine weakly inhibits the uptake of serotonin.	Harmine	89-96	monoamine oxidase A	Homo sapiens	130-149
10404423-2	1999	Such beverages are characterized by the presence of these three harmala alkaloids, where harmine and harmaline reversibly inhibit monoamine oxidase A (MAO-A) while tetrahydroharmine weakly inhibits the uptake of serotonin.	Harmine	89-96	monoamine oxidase A	Homo sapiens	151-156
7667371-4	1995	For example, both MDA and BDB produced abnormal body posture that was identical to that reported after administration of hallucinogens such as lysergic acid diethylamide (LSD) and harmine (11).	Harmine	180-187	receptor tyrosine kinase like orphan receptor 2	Homo sapiens	26-29
9257326-5	1997	Different approaches for a quantitative determination of MAO-A enzyme binding were attempted and demonstrated an IC50 dose of harmine in the range of 0.05-0.1 mg/kg.	Harmine	126-133	monoamine oxidase A	Rattus norvegicus	57-62
8990278-6	1997	Harmine, 2-methylharminium, 2,9-dimethylharminium, and harmaline were the most effective inhibitors of the purified MAO A, with low Ki values of 5, 69, 15, and 48 nM, respectively.	Harmine	0-7	monoamine oxidase A	Homo sapiens	116-121
7667371-6	1995	BDB also produced bursting forward movements, an effect commonly observed after LSD and harmine.	Harmine	88-95	receptor tyrosine kinase like orphan receptor 2	Homo sapiens	0-3
34242659-9	2022	TWIST1 inhibitor harmine could significantly suppress the fibrogenesis of keloid fibroblasts.	Harmine	17-24	twist family bHLH transcription factor 1	Homo sapiens	0-6
2137718-4	1990	The partially competitive nature of inhibition by one of the more effective pairs, 2-methyl-harmine and harmine, was consistent with uptake of the beta-carbolines by the synaptosomal dopamine uptake system, as was the fact that the accumulation of 2-[14C]methyl-harmine was significantly reduced by low Na+ media and by nomifensine, a potent inhibitor of the dopamine transporter.	Harmine	92-99	solute carrier family 6 member 3	Homo sapiens	359-379
33234703-6	2020	An investigation into the mechanism revealed that harmine, when used with LRAs, increased the activity of NFkappaB, MAPK p38, and ERK1/2.	Harmine	50-57	mitogen-activated protein kinase 3	Homo sapiens	130-136
33234703-7	2020	Harmine treatment also resulted in reduced expression of HEXIM1, a negative regulator of transcriptional elongation.	Harmine	0-7	HEXIM P-TEFb complex subunit 1	Homo sapiens	57-63
34098466-0	2021	Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3beta/DYRK1A dual inhibitors for the treatment of Alzheimer"s disease.	Harmine	47-54	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	87-93
34952543-3	2021	Therefore, 18 179 mRNA expression maps (based on the Allen Human Brain Atlas) were correlated with the cerebral distribution volume (VT) of MAO-A assessed in 36 healthy subjects (mean age +- standard deviation: 32.9 +- 8.8 years, 18 female) using (11C)harmine positron emission tomography scans.	Harmine	252-259	monoamine oxidase A	Homo sapiens	140-145
34098466-0	2021	Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3beta/DYRK1A dual inhibitors for the treatment of Alzheimer"s disease.	Harmine	47-54	glycogen synthase kinase 3 alpha	Homo sapiens	77-86
34098466-4	2021	In this study, a new series of harmine derivatives were designed, synthesized and evaluated as dual GSK-3beta/DYRK1A inhibitors for their multiple biological activities.	Harmine	31-38	glycogen synthase kinase 3 alpha	Homo sapiens	100-109
34098466-4	2021	In this study, a new series of harmine derivatives were designed, synthesized and evaluated as dual GSK-3beta/DYRK1A inhibitors for their multiple biological activities.	Harmine	31-38	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	110-116
34079546-9	2021	And we also provided evidences that the immunomodulatory capacity of harmine might be attributed to the inhibition of the c-Jun N-terminal kinase (JNK) in wear particle-treated macrophages.	Harmine	69-76	mitogen-activated protein kinase 8	Mus musculus	122-145
34205249-5	2021	Of these compounds, synephrine, trigonelline, cytisine, harmine, koumine, peimisine, and hupehenine exhibited in vitro inhibition of alpha-syn-seeded fibril formation.	Harmine	56-63	synuclein alpha	Homo sapiens	133-142
34384998-0	2021	Cell-based assays and molecular simulation reveal that the anti-cancer harmine is a specific matrix metalloproteinase-3 (MMP-3) inhibitor.	Harmine	71-78	matrix metallopeptidase 3	Homo sapiens	93-119
34384998-0	2021	Cell-based assays and molecular simulation reveal that the anti-cancer harmine is a specific matrix metalloproteinase-3 (MMP-3) inhibitor.	Harmine	71-78	matrix metallopeptidase 3	Homo sapiens	121-126
34384998-3	2021	We therefore investigated harmine for its effects on MMP-3 and the molecular interaction was also simulated.	Harmine	26-33	matrix metallopeptidase 3	Homo sapiens	53-58
34384998-5	2021	These results showed that although harmine stimulation in vitro has very little or no effects on MMP-3 expression by U-87 MG cells, the treatment of harmine decreases MMP-3 activity in a dose dependent manner.	Harmine	149-156	matrix metallopeptidase 3	Homo sapiens	97-102
34384998-5	2021	These results showed that although harmine stimulation in vitro has very little or no effects on MMP-3 expression by U-87 MG cells, the treatment of harmine decreases MMP-3 activity in a dose dependent manner.	Harmine	149-156	matrix metallopeptidase 3	Homo sapiens	167-172
34384998-7	2021	Using a molecular dynamic simulation approach, we identified the N2, methyl of C1 and benzene ring of harmine interact with Zn2+ (2.4 A), His205 (2.4 A) and His211 (2.4 A) as well as Val163 (2.7 A) at the active site of MMP-3, respectively, and thus conferred a striking specific binding advantage.	Harmine	102-109	matrix metallopeptidase 3	Homo sapiens	220-225
34384998-8	2021	Taken altogether, the present study evidences that harmine acts as an MMP-3 inhibitor specially targeting the enzymatic active site and possibly efficiently ameliorates MMP-3-driven malignant and inflammatory diseases.	Harmine	51-58	matrix metallopeptidase 3	Homo sapiens	70-75
34384998-8	2021	Taken altogether, the present study evidences that harmine acts as an MMP-3 inhibitor specially targeting the enzymatic active site and possibly efficiently ameliorates MMP-3-driven malignant and inflammatory diseases.	Harmine	51-58	matrix metallopeptidase 3	Homo sapiens	169-174
34425477-5	2021	A series of novel benzo(d)imidazo(2,1-b)thiazole derivatives possessing 1,3,4-oxadiazole moiety were designed based on the structure of the first-in-class Twist1 inhibitor harmine.	Harmine	172-179	twist family bHLH transcription factor 1	Homo sapiens	155-161
34425477-7	2021	Meanwhile, western blot assay showed that the optimal compound significantly down-regulated Twist1 protein expression in a dose-dependent manner and reduced Twist1 level better than harmine.	Harmine	182-189	twist family bHLH transcription factor 1	Homo sapiens	92-98
34425477-7	2021	Meanwhile, western blot assay showed that the optimal compound significantly down-regulated Twist1 protein expression in a dose-dependent manner and reduced Twist1 level better than harmine.	Harmine	182-189	twist family bHLH transcription factor 1	Homo sapiens	157-163
34079546-9	2021	And we also provided evidences that the immunomodulatory capacity of harmine might be attributed to the inhibition of the c-Jun N-terminal kinase (JNK) in wear particle-treated macrophages.	Harmine	69-76	mitogen-activated protein kinase 8	Mus musculus	147-150
35569122-10	2022	CMap analysis showed that the small molecules scriptaid, torasemide, dexpropranolol, ipratropium bromide, and harmine were potential negative regulators of TGIF1.	Harmine	110-117	TGFB induced factor homeobox 1	Homo sapiens	156-161
34078836-11	2021	CONCLUSION: Harmine exposure leads to central neurological symptoms, cardiovascular effects and even death through direct inhibition of the central AChE activity, where the death primarily comes from central neurological symptoms and is cooperated by the secondary cardiovascular collapse.	Harmine	12-19	acetylcholinesterase	Mus musculus	148-152
35623405-0	2022	Harmine prevents 3-nitropropionic acid-induced neurotoxicity in rats via enhancing NRF2-mediated signaling: Involvement of p21 and AMPK.	Harmine	0-7	NFE2 like bZIP transcription factor 2	Rattus norvegicus	83-87
35623405-0	2022	Harmine prevents 3-nitropropionic acid-induced neurotoxicity in rats via enhancing NRF2-mediated signaling: Involvement of p21 and AMPK.	Harmine	0-7	KRAS proto-oncogene, GTPase	Rattus norvegicus	123-126
35623405-0	2022	Harmine prevents 3-nitropropionic acid-induced neurotoxicity in rats via enhancing NRF2-mediated signaling: Involvement of p21 and AMPK.	Harmine	0-7	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	131-135
35623405-3	2022	This study aimed at evaluating the prophylactic effects of the dual-specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) inhibitor "harmine" against 3-NP-indued neurotoxicity and HD-like symptoms.	Harmine	145-152	dual specificity tyrosine phosphorylation regulated kinase 1A	Rattus norvegicus	63-124
35623405-3	2022	This study aimed at evaluating the prophylactic effects of the dual-specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) inhibitor "harmine" against 3-NP-indued neurotoxicity and HD-like symptoms.	Harmine	145-152	dual specificity tyrosine phosphorylation regulated kinase 1A	Rattus norvegicus	126-132
35623405-5	2022	Harmine successfully increased the protein levels of NRF2, AMPK and p21 and the gene expression of Ho-1, Nqo-1 and p62, restored redox homeostasis, and reduced CASPASE-3 level.	Harmine	0-7	NFE2 like bZIP transcription factor 2	Rattus norvegicus	53-57
35623405-5	2022	Harmine successfully increased the protein levels of NRF2, AMPK and p21 and the gene expression of Ho-1, Nqo-1 and p62, restored redox homeostasis, and reduced CASPASE-3 level.	Harmine	0-7	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	59-63
35623405-5	2022	Harmine successfully increased the protein levels of NRF2, AMPK and p21 and the gene expression of Ho-1, Nqo-1 and p62, restored redox homeostasis, and reduced CASPASE-3 level.	Harmine	0-7	KRAS proto-oncogene, GTPase	Rattus norvegicus	68-71
35623405-5	2022	Harmine successfully increased the protein levels of NRF2, AMPK and p21 and the gene expression of Ho-1, Nqo-1 and p62, restored redox homeostasis, and reduced CASPASE-3 level.	Harmine	0-7	heme oxygenase 1	Rattus norvegicus	99-103
35623405-5	2022	Harmine successfully increased the protein levels of NRF2, AMPK and p21 and the gene expression of Ho-1, Nqo-1 and p62, restored redox homeostasis, and reduced CASPASE-3 level.	Harmine	0-7	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	105-110
35623405-5	2022	Harmine successfully increased the protein levels of NRF2, AMPK and p21 and the gene expression of Ho-1, Nqo-1 and p62, restored redox homeostasis, and reduced CASPASE-3 level.	Harmine	0-7	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	115-118
35623405-5	2022	Harmine successfully increased the protein levels of NRF2, AMPK and p21 and the gene expression of Ho-1, Nqo-1 and p62, restored redox homeostasis, and reduced CASPASE-3 level.	Harmine	0-7	caspase 3	Rattus norvegicus	160-169
35623405-7	2022	This study draws attention to the protective role of harmine against 3-NP-induced motor and cognitive dysfunction that could be mediated via enhancing NRF2-mediated signaling with subsequent amelioration of oxidative stress injury via NRF2 activators, p21 and AMPK, in the striatum, prefrontal cortex, and hippocampus which could offer a promising therapeutic tool to slow the progression of HD.	Harmine	53-60	NFE2 like bZIP transcription factor 2	Rattus norvegicus	151-155
35623405-7	2022	This study draws attention to the protective role of harmine against 3-NP-induced motor and cognitive dysfunction that could be mediated via enhancing NRF2-mediated signaling with subsequent amelioration of oxidative stress injury via NRF2 activators, p21 and AMPK, in the striatum, prefrontal cortex, and hippocampus which could offer a promising therapeutic tool to slow the progression of HD.	Harmine	53-60	NFE2 like bZIP transcription factor 2	Rattus norvegicus	235-239
35623405-7	2022	This study draws attention to the protective role of harmine against 3-NP-induced motor and cognitive dysfunction that could be mediated via enhancing NRF2-mediated signaling with subsequent amelioration of oxidative stress injury via NRF2 activators, p21 and AMPK, in the striatum, prefrontal cortex, and hippocampus which could offer a promising therapeutic tool to slow the progression of HD.	Harmine	53-60	KRAS proto-oncogene, GTPase	Rattus norvegicus	252-255
35623405-7	2022	This study draws attention to the protective role of harmine against 3-NP-induced motor and cognitive dysfunction that could be mediated via enhancing NRF2-mediated signaling with subsequent amelioration of oxidative stress injury via NRF2 activators, p21 and AMPK, in the striatum, prefrontal cortex, and hippocampus which could offer a promising therapeutic tool to slow the progression of HD.	Harmine	53-60	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	260-264
35219102-0	2022	Harmine suppresses collagen production in hepatic stellate cells by inhibiting DYRK1B.	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1B	Homo sapiens	79-85
35369706-4	2022	RESULTS: We observed that harmine, an inhibitor of DYRK1a, improved left ventricular ejection fraction (39.5+-1.6% and 29.1+-1.6%, harmine versus placebo, respectively), 2 weeks after I/R MI.	Harmine	26-33	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	51-57
35219102-8	2022	Harmine (10 muM) significantly inhibited the increased expression of COL1A1.	Harmine	0-7	collagen, type I, alpha 1	Mus musculus	69-75
35244188-5	2022	In addition, DYRK1A knockdown using small interfering RNA transfection or treatment with harmine, a natural alkaloid, significantly reduced the protein expression levels of HIF-1alpha in liver cancer cells under hypoxic conditions in vitro.	Harmine	89-96	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	13-19
35219102-11	2022	These results suggest that harmine suppresses COL1A1 expression via inhibiting DYRK1B in HSCs and therefore might be effective for the treatment of liver fibrosis.	Harmine	27-34	collagen type I alpha 1 chain	Homo sapiens	46-52
35219102-11	2022	These results suggest that harmine suppresses COL1A1 expression via inhibiting DYRK1B in HSCs and therefore might be effective for the treatment of liver fibrosis.	Harmine	27-34	dual specificity tyrosine phosphorylation regulated kinase 1B	Homo sapiens	79-85
35244188-5	2022	In addition, DYRK1A knockdown using small interfering RNA transfection or treatment with harmine, a natural alkaloid, significantly reduced the protein expression levels of HIF-1alpha in liver cancer cells under hypoxic conditions in vitro.	Harmine	89-96	hypoxia inducible factor 1 subunit alpha	Homo sapiens	173-183
35244188-11	2022	Co-treatment with harmine and either regorafenib or sorafenib also promoted cell death via the STAT3/HIF-1alpha/AKT signaling pathway under hypoxia using PI staining and western blotting.	Harmine	18-25	signal transducer and activator of transcription 3	Homo sapiens	95-100
35244188-11	2022	Co-treatment with harmine and either regorafenib or sorafenib also promoted cell death via the STAT3/HIF-1alpha/AKT signaling pathway under hypoxia using PI staining and western blotting.	Harmine	18-25	hypoxia inducible factor 1 subunit alpha	Homo sapiens	101-111
35244188-11	2022	Co-treatment with harmine and either regorafenib or sorafenib also promoted cell death via the STAT3/HIF-1alpha/AKT signaling pathway under hypoxia using PI staining and western blotting.	Harmine	18-25	AKT serine/threonine kinase 1	Homo sapiens	112-115
3876687-6	1985	In ethanol-withdrawn rats treated with harmine or LON-954 the frequency analysis of tremor revealed a narrow peak frequency at about 12 Hz, which was neither the characteristic frequency of ethanol withdrawal tremor (6 Hz) nor that of harmine or LON-954 (10 Hz).	Harmine	39-46	lon peptidase 1, mitochondrial	Rattus norvegicus	246-249
35126712-6	2022	Furthermore, DYRK1A inhibitor harmine together with regorafenib provided synergistic anti-liver cancer activity by suppressing cell proliferation.	Harmine	30-37	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	13-19
35126712-9	2022	In the present study, AKT was activated in regorafenib-treated cells, and harmine could suppress the activation of AKT and reinforce the anti-cancer effects of regorafenib via regulating AKT in liver cancer cells.	Harmine	74-81	AKT serine/threonine kinase 1	Homo sapiens	115-118
35126712-9	2022	In the present study, AKT was activated in regorafenib-treated cells, and harmine could suppress the activation of AKT and reinforce the anti-cancer effects of regorafenib via regulating AKT in liver cancer cells.	Harmine	74-81	AKT serine/threonine kinase 1	Homo sapiens	187-190
35126712-10	2022	These data indicated that harmine enhanced the anti-cancer effects of regorafenib on suppressing cell proliferation and inducing apoptosis in liver cancer cells via regulating the activation of AKT, and harmine plus regorafenib may be a potential therapeutic regimen for treating patients with liver cancer.	Harmine	26-33	AKT serine/threonine kinase 1	Homo sapiens	194-197
35111758-0	2021	Harmine Alleviated Sepsis-Induced Cardiac Dysfunction by Modulating Macrophage Polarization via the STAT/MAPK/NF-kappaB Pathway.	Harmine	0-7	signal transducer and activator of transcription 1	Mus musculus	100-104
35111758-0	2021	Harmine Alleviated Sepsis-Induced Cardiac Dysfunction by Modulating Macrophage Polarization via the STAT/MAPK/NF-kappaB Pathway.	Harmine	0-7	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	110-119
35111758-4	2021	In vitro, the expression of the M1 phenotype markers iNOS and COX-2 was increased in RAW 264.7 cells stimulated with lipopolysaccharide (LPS), but this effect was reversed by the harmine intervention.	Harmine	179-186	nitric oxide synthase 2, inducible	Mus musculus	53-57
35111758-4	2021	In vitro, the expression of the M1 phenotype markers iNOS and COX-2 was increased in RAW 264.7 cells stimulated with lipopolysaccharide (LPS), but this effect was reversed by the harmine intervention.	Harmine	179-186	cytochrome c oxidase II, mitochondrial	Mus musculus	62-67
35111758-6	2021	Meanwhile, our findings showed that harmine administration effectively attenuated inflammation and apoptosis in H9c2 cells in the proinflammatory environment produced by macrophages, as evidenced by reductions in NLRP3 and cleaved caspase 3 levels and the p-NF-kappaB/NF-kappaB ratio.	Harmine	36-43	NLR family, pyrin domain containing 3	Rattus norvegicus	213-218
35111758-6	2021	Meanwhile, our findings showed that harmine administration effectively attenuated inflammation and apoptosis in H9c2 cells in the proinflammatory environment produced by macrophages, as evidenced by reductions in NLRP3 and cleaved caspase 3 levels and the p-NF-kappaB/NF-kappaB ratio.	Harmine	36-43	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	258-267
35111758-6	2021	Meanwhile, our findings showed that harmine administration effectively attenuated inflammation and apoptosis in H9c2 cells in the proinflammatory environment produced by macrophages, as evidenced by reductions in NLRP3 and cleaved caspase 3 levels and the p-NF-kappaB/NF-kappaB ratio.	Harmine	36-43	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	268-277
35111758-7	2021	The western blot results indicated that the mechanisms underlying harmine-mediated inhibition of M1 polarization might be associated with suppression of STAT1/3, NF-kappaB and MAPK activation.	Harmine	66-73	signal transducer and activator of transcription 1	Mus musculus	153-160
35111758-7	2021	The western blot results indicated that the mechanisms underlying harmine-mediated inhibition of M1 polarization might be associated with suppression of STAT1/3, NF-kappaB and MAPK activation.	Harmine	66-73	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	162-171
35053488-7	2022	Additionally, we demonstrated that the harmine-targeted suppression of DYRK1A used in conjunction with radiotherapy increases DNA double-strand breaks (DSBs) and impairs homologous repair (HR), resulting in more cancer cell death.	Harmine	39-46	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	71-77
34994084-0	2022	Rational Design and Identification of Harmine-Inspired, N-Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System.	Harmine	38-45	minibrain	Drosophila melanogaster	71-77
34710745-8	2022	Compound b1 and harmine were more efficient in protecting SH-SY5Y cells against 6-hydroxydopamine-induced cell death, an effect that was previously correlated to Dyrk1A inactivation in cells but not yet verified using chemical inhibitors.	Harmine	16-23	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	162-168
522515-2	1979	Isolated intestinal cells catalyzed the cytochrome P-450 dependent metabolism of benzo(a)pyrene, harmine, ethoxyresorufin and ethoxycoumarin.	Harmine	97-104	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	40-56
3896805-1	1985	In this study we show that harmine treatment (10 mg/l for 2 or 24 h) of PtK2 cells had a marked effect on the localization of the nucleolar phosphoproteins C23 and B23.	Harmine	27-34	protein tyrosine kinase 2	Homo sapiens	72-76
3896805-1	1985	In this study we show that harmine treatment (10 mg/l for 2 or 24 h) of PtK2 cells had a marked effect on the localization of the nucleolar phosphoproteins C23 and B23.	Harmine	27-34	nucleolin	Homo sapiens	156-159
6279462-1	1982	Inhibition of pineal monoamine oxidase (MAO) activity either by harmine or pargyline in adult male Sprague-Dawley rats housed in a 12 : 12 LD cycle resulted in increase pineal N-acetyltransferase (NAT) activity.	Harmine	64-71	monoamine oxidase A	Rattus norvegicus	21-38
6279462-1	1982	Inhibition of pineal monoamine oxidase (MAO) activity either by harmine or pargyline in adult male Sprague-Dawley rats housed in a 12 : 12 LD cycle resulted in increase pineal N-acetyltransferase (NAT) activity.	Harmine	64-71	monoamine oxidase A	Rattus norvegicus	40-43
6310434-0	1983	Cholecystokinin octapeptide (CCK-8), ceruletide and analogues of ceruletide: effects on tremors induced by oxotremorine, harmine and ibogaine.	Harmine	121-128	cholecystokinin	Mus musculus	0-15
461984-5	1979	One must consider the inhibitory effect of harmine and harmaline on both MAO and N-acetyltransferase when evaluating the effects of these compounds on physiological processes.	Harmine	43-50	monoamine oxidase A	Rattus norvegicus	73-76
33960660-8	2021	Dual-luciferase reporter assay analyses determined that PDGF-BB was the direct target of AP-1 which was up-regulated by harmine treatment.	Harmine	120-127	jun proto-oncogene	Mus musculus	89-93
12389-8	1976	The pI curves for inhibition of MAO activity by harmine, pargyline and iproniazid were similar and almost the same pI 50 values for the respective inhibitors were obtained with the two substrates.	Harmine	48-55	monoamine oxidase A	Rattus norvegicus	32-35
33960660-0	2021	Harmine targets inhibitor of DNA binding-2 and activator protein-1 to promote preosteoclast PDGF-BB production.	Harmine	0-7	jun proto-oncogene	Mus musculus	47-66
132195-3	1976	Harmine and harmaline were investigated as potentially useful fluorescent inhibitors of (Na+ + K+) activated ATPase.	Harmine	0-7	dynein axonemal heavy chain 8	Homo sapiens	109-115
34050242-8	2021	Harmine potently stimulated alpha-cell proliferation and both harmine and HB-EGF increased proliferation of insulin- and glucagon-negative cells, including cytokeratin 19-positive cells.	Harmine	62-69	insulin	Homo sapiens	108-115
34050242-8	2021	Harmine potently stimulated alpha-cell proliferation and both harmine and HB-EGF increased proliferation of insulin- and glucagon-negative cells, including cytokeratin 19-positive cells.	Harmine	62-69	glucagon	Homo sapiens	121-129
34050242-8	2021	Harmine potently stimulated alpha-cell proliferation and both harmine and HB-EGF increased proliferation of insulin- and glucagon-negative cells, including cytokeratin 19-positive cells.	Harmine	62-69	keratin 19	Homo sapiens	156-170
34030962-0	2021	A natural compound harmine decreases melanin synthesis through regulation of the DYRK1A/NFATC3 pathway.	Harmine	19-26	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	81-87
34030962-0	2021	A natural compound harmine decreases melanin synthesis through regulation of the DYRK1A/NFATC3 pathway.	Harmine	19-26	nuclear factor of activated T cells 3	Homo sapiens	88-94
34030962-7	2021	Inhibition of DYRK1A, a harmine target, decreased melanin synthesis and tyrosinase expression.	Harmine	24-31	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	14-20
34030962-10	2021	Furthermore, harmine also decreased melanin synthesis and tyrosinase expression through regulation of NFATC3 in human primary melanocytes.	Harmine	13-20	nuclear factor of activated T cells 3	Homo sapiens	102-108
34030962-11	2021	CONCLUSION: Our results indicate that harmine decreases melanin synthesis through regulation of the DYRK1A/NFATC3 pathway and suggest that the DYRK1A/NFATC3 pathway may be a potential target for the development of depigmenting agents.	Harmine	38-45	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	100-106
34030962-11	2021	CONCLUSION: Our results indicate that harmine decreases melanin synthesis through regulation of the DYRK1A/NFATC3 pathway and suggest that the DYRK1A/NFATC3 pathway may be a potential target for the development of depigmenting agents.	Harmine	38-45	nuclear factor of activated T cells 3	Homo sapiens	107-113
34030962-11	2021	CONCLUSION: Our results indicate that harmine decreases melanin synthesis through regulation of the DYRK1A/NFATC3 pathway and suggest that the DYRK1A/NFATC3 pathway may be a potential target for the development of depigmenting agents.	Harmine	38-45	nuclear factor of activated T cells 3	Homo sapiens	150-156
33960660-4	2021	In this study, we revealed that inhibitor of DNA binding-2 (Id2) and activator protein-1 (AP-1) were important factors implicated in harmine-enhanced preosteoclast PDGF-BB production.	Harmine	133-140	inhibitor of DNA binding 2	Mus musculus	32-58
33960660-4	2021	In this study, we revealed that inhibitor of DNA binding-2 (Id2) and activator protein-1 (AP-1) were important factors implicated in harmine-enhanced preosteoclast PDGF-BB production.	Harmine	133-140	inhibitor of DNA binding 2	Mus musculus	60-63
33960660-4	2021	In this study, we revealed that inhibitor of DNA binding-2 (Id2) and activator protein-1 (AP-1) were important factors implicated in harmine-enhanced preosteoclast PDGF-BB production.	Harmine	133-140	jun proto-oncogene	Mus musculus	69-88
33960660-4	2021	In this study, we revealed that inhibitor of DNA binding-2 (Id2) and activator protein-1 (AP-1) were important factors implicated in harmine-enhanced preosteoclast PDGF-BB production.	Harmine	133-140	jun proto-oncogene	Mus musculus	90-94
33948561-8	2021	Inhibition of ABCB1 was mediated by vardenafil, and TWIST1 expression was reduced by either Harmine or shRNA.	Harmine	92-99	twist basic helix-loop-helix transcription factor 1	Mus musculus	52-58
33960660-5	2021	Exposure of RANKL-induced Primary bone marrow macrophages (BMMs), isolated from tibiae and femora of mice, to harmine increased the protein levels of Id2 and AP-1.	Harmine	110-117	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	12-17
33960660-5	2021	Exposure of RANKL-induced Primary bone marrow macrophages (BMMs), isolated from tibiae and femora of mice, to harmine increased the protein levels of Id2 and AP-1.	Harmine	110-117	inhibitor of DNA binding 2	Mus musculus	150-153
33960660-5	2021	Exposure of RANKL-induced Primary bone marrow macrophages (BMMs), isolated from tibiae and femora of mice, to harmine increased the protein levels of Id2 and AP-1.	Harmine	110-117	jun proto-oncogene	Mus musculus	158-162
33960660-6	2021	Knockdown of Id2 by Id2-siRNA reduced the number of preosteoclasts as well as secretion of PDGF-BB in RANKL-stimulated BMMs administrated with harmine.	Harmine	143-150	inhibitor of DNA binding 2	Mus musculus	13-16
33960660-6	2021	Knockdown of Id2 by Id2-siRNA reduced the number of preosteoclasts as well as secretion of PDGF-BB in RANKL-stimulated BMMs administrated with harmine.	Harmine	143-150	inhibitor of DNA binding 2	Mus musculus	20-23
33960660-6	2021	Knockdown of Id2 by Id2-siRNA reduced the number of preosteoclasts as well as secretion of PDGF-BB in RANKL-stimulated BMMs administrated with harmine.	Harmine	143-150	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	102-107
33960660-7	2021	Inhibition of c-Fos or c-Jun (components of AP-1) both reversed the stimulatory effect of harmine on preosteoclast PDGF-BB production.	Harmine	90-97	FBJ osteosarcoma oncogene	Mus musculus	14-19
33960660-7	2021	Inhibition of c-Fos or c-Jun (components of AP-1) both reversed the stimulatory effect of harmine on preosteoclast PDGF-BB production.	Harmine	90-97	jun proto-oncogene	Mus musculus	23-28
33960660-7	2021	Inhibition of c-Fos or c-Jun (components of AP-1) both reversed the stimulatory effect of harmine on preosteoclast PDGF-BB production.	Harmine	90-97	jun proto-oncogene	Mus musculus	44-48
33636211-7	2021	The objectives of the present study were to optimise non-radiolabelled harmine and deprenyl as selective tracers in MAO-A and MAO-B occupancy assays and evaluate MAO occupancy of test compounds in rat brain.	Harmine	71-78	monoamine oxidase A	Rattus norvegicus	116-121
33636211-11	2021	Pre-treatment with MAO inhibitors resulted in a decrease (maximum, 80-85%) in harmine or an increase (maximum, 85-300%) in L-deprenyl concentrations.	Harmine	78-85	monoamine oxidase A	Rattus norvegicus	19-22
33713497-7	2021	Similar results were obtained with topical application of harmine, a Harmala alkaloid that leads to degradation of Twist1.	Harmine	58-65	twist basic helix-loop-helix transcription factor 1	Mus musculus	115-121
33474722-0	2021	Harmine alleviates atherogenesis by inhibiting disturbed flow-mediated endothelial activation via PTPN14/YAP.	Harmine	0-7	protein tyrosine phosphatase, non-receptor type 14	Mus musculus	98-104
33474722-0	2021	Harmine alleviates atherogenesis by inhibiting disturbed flow-mediated endothelial activation via PTPN14/YAP.	Harmine	0-7	yes-associated protein 1	Mus musculus	105-108
33474722-4	2021	EXPERIMENTAL APPROACH: Mice of ApoE-/- , LDLR-/- and endothelial cell (EC)-specific overexpression of Yes-associated protein (YAP) in ApoE-/- background were fed a western diet and given harmine for 4 weeks.	Harmine	187-194	yes-associated protein 1	Mus musculus	102-124
33474722-4	2021	EXPERIMENTAL APPROACH: Mice of ApoE-/- , LDLR-/- and endothelial cell (EC)-specific overexpression of Yes-associated protein (YAP) in ApoE-/- background were fed a western diet and given harmine for 4 weeks.	Harmine	187-194	yes-associated protein 1	Mus musculus	126-129
33474722-4	2021	EXPERIMENTAL APPROACH: Mice of ApoE-/- , LDLR-/- and endothelial cell (EC)-specific overexpression of Yes-associated protein (YAP) in ApoE-/- background were fed a western diet and given harmine for 4 weeks.	Harmine	187-194	apolipoprotein E	Mus musculus	134-138
33474722-7	2021	KEY RESULTS: Harmine retarded atherogenesis in both ApoE-/- and LDLR-/- mice by inhibiting the endothelial inflammatory response.	Harmine	13-20	apolipoprotein E	Mus musculus	52-56
33474722-7	2021	KEY RESULTS: Harmine retarded atherogenesis in both ApoE-/- and LDLR-/- mice by inhibiting the endothelial inflammatory response.	Harmine	13-20	low density lipoprotein receptor	Mus musculus	64-68
33474722-8	2021	Mechanistically, harmine blocked OSS-induced YAP nuclear translocation and EC activation by reducing phosphorylation of YAP at Y357.	Harmine	17-24	yes-associated protein 1	Mus musculus	45-48
33474722-8	2021	Mechanistically, harmine blocked OSS-induced YAP nuclear translocation and EC activation by reducing phosphorylation of YAP at Y357.	Harmine	17-24	yes-associated protein 1	Mus musculus	120-123
33474722-9	2021	Overexpression of endothelial YAP blunted the beneficial effects of harmine in mice.	Harmine	68-75	yes-associated protein 1	Mus musculus	30-33
33474722-11	2021	Moreover, harmine increased PTPN14 expression by stabilizing its protein level and inhibiting its degradation in proteasome.	Harmine	10-17	protein tyrosine phosphatase, non-receptor type 14	Mus musculus	28-34
33474722-12	2021	PTPN14 knockdown blocked the effects of harmine on YAPY357 and EC activation.	Harmine	40-47	protein tyrosine phosphatase, non-receptor type 14	Mus musculus	0-6
33474722-13	2021	Finally, overexpression of PTPN14 mimicked the effects of harmine and ameliorated atherosclerosis, and knockdown of PTPN14 blunted the atheroprotective effects of harmine and accelerated atherosclerosis, in a partial ligation mouse model.	Harmine	58-65	protein tyrosine phosphatase, non-receptor type 14	Mus musculus	27-33
33474722-13	2021	Finally, overexpression of PTPN14 mimicked the effects of harmine and ameliorated atherosclerosis, and knockdown of PTPN14 blunted the atheroprotective effects of harmine and accelerated atherosclerosis, in a partial ligation mouse model.	Harmine	163-170	protein tyrosine phosphatase, non-receptor type 14	Mus musculus	116-122
33474722-14	2021	CONCLUSION AND IMPLICATIONS: Harmine alleviated OSS-induced EC activation via a PTPN14/YAPY357 pathway and had a potent athero-protective role.	Harmine	29-36	protein tyrosine phosphatase, non-receptor type 14	Mus musculus	80-86
33508300-0	2021	Harmine inhibits the proliferation and migration of glioblastoma cells via the FAK/AKT pathway.	Harmine	0-7	protein tyrosine kinase 2	Homo sapiens	79-82
33508300-0	2021	Harmine inhibits the proliferation and migration of glioblastoma cells via the FAK/AKT pathway.	Harmine	0-7	AKT serine/threonine kinase 1	Homo sapiens	83-86
33508300-10	2021	Mechanistically, harmine reduced the basal and EGF-enhanced the phosphorylation level of FAK and AKT.	Harmine	17-24	protein tyrosine kinase 2	Homo sapiens	89-92
33508300-10	2021	Mechanistically, harmine reduced the basal and EGF-enhanced the phosphorylation level of FAK and AKT.	Harmine	17-24	AKT serine/threonine kinase 1	Homo sapiens	97-100
33508300-11	2021	Moreover, harmine inhibited the cell viability of U251-MG and U373-MG cells by downregulating the phosphorylation of the FAK/AKT pathway.	Harmine	10-17	protein tyrosine kinase 2	Homo sapiens	121-124
33508300-11	2021	Moreover, harmine inhibited the cell viability of U251-MG and U373-MG cells by downregulating the phosphorylation of the FAK/AKT pathway.	Harmine	10-17	AKT serine/threonine kinase 1	Homo sapiens	125-128
33508300-12	2021	Besides, harmine significantly suppressed the migration of U251-MG cells by suppressing the expression of MMP2, MMP9 and VEGF.	Harmine	9-16	matrix metallopeptidase 2	Homo sapiens	106-110
33508300-12	2021	Besides, harmine significantly suppressed the migration of U251-MG cells by suppressing the expression of MMP2, MMP9 and VEGF.	Harmine	9-16	matrix metallopeptidase 9	Homo sapiens	112-116
33508300-12	2021	Besides, harmine significantly suppressed the migration of U251-MG cells by suppressing the expression of MMP2, MMP9 and VEGF.	Harmine	9-16	vascular endothelial growth factor A	Homo sapiens	121-125
33508300-14	2021	SIGNIFICANCE: In conclusion, these results suggest that harmine suppresses the proliferation and migration of U251-MG and U373-MG cells by inhibiting the FAK/AKT signaling pathway.	Harmine	56-63	protein tyrosine kinase 2	Homo sapiens	154-157
33508300-14	2021	SIGNIFICANCE: In conclusion, these results suggest that harmine suppresses the proliferation and migration of U251-MG and U373-MG cells by inhibiting the FAK/AKT signaling pathway.	Harmine	56-63	AKT serine/threonine kinase 1	Homo sapiens	158-161
33785860-6	2022	We further showed that one of the potential underlying mechanism by which harmine alleviates cardiac hypertrophy relied on inhibition of NF-kappaB phosphorylation and the stimulated inflammatory cytokines in pathological ventricular remodeling.	Harmine	74-81	nuclear factor kappa B subunit 1	Homo sapiens	137-146
33626096-0	2021	Harmine inhibits breast cancer cell migration and invasion by inducing the degradation of Twist1.	Harmine	0-7	twist family bHLH transcription factor 1	Homo sapiens	90-96
33626096-4	2021	Harmine is a beta-carboline alkaloid found in a variety of plants and was recently shown to be able to induce degradation of Twist Family BHLH Transcription Factor 1 (Twist1) in non-small cell lung cancer cells (NSCLC).	Harmine	0-7	twist family bHLH transcription factor 1	Homo sapiens	125-165
33626096-4	2021	Harmine is a beta-carboline alkaloid found in a variety of plants and was recently shown to be able to induce degradation of Twist Family BHLH Transcription Factor 1 (Twist1) in non-small cell lung cancer cells (NSCLC).	Harmine	0-7	twist family bHLH transcription factor 1	Homo sapiens	167-173
32926882-3	2020	The primary goal of this study was to evaluate the abuse potential of the beta-carbolines harmane, norharmane, and harmine - MAO inhibitors that are found in cigarette smoke - in an intracranial self-simulation (ICSS) model in rats.	Harmine	115-122	monoamine oxidase A	Rattus norvegicus	125-128
33480316-0	2021	Structure-activity insights of harmine targeting DNA, ROS inducing cytotoxicity with PARP mediated apoptosis against cervical cancer, anti-biofilm formation and in vivo therapeutic study.	Harmine	31-38	poly (ADP-ribose) polymerase family, member 1	Mus musculus	85-89
33480316-9	2021	Harmine exhibited G2M arrest with ROS induced effective role in PARP mediated apoptosis as well as anti-inflammatory action on HeLa cells.	Harmine	0-7	collagen type XI alpha 2 chain	Homo sapiens	64-68
33183209-10	2021	CONCLUSION: Harmine and Harmaline exhibit higher binding affinity towards D2- and D3- dopamine receptors compared to L-DOPA, and PKs and toxicity profile support their potential as drug candidates for PD therapy.	Harmine	12-19	dopamine receptor D2	Homo sapiens	74-104
33339338-0	2020	How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine.	Harmine	145-152	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	103-109
33339338-1	2020	The beta-carboline alkaloid harmine is a potent DYRK1A inhibitor, but suffers from undesired potent inhibition of MAO-A, which strongly limits its application.	Harmine	28-35	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	48-54
33339338-1	2020	The beta-carboline alkaloid harmine is a potent DYRK1A inhibitor, but suffers from undesired potent inhibition of MAO-A, which strongly limits its application.	Harmine	28-35	monoamine oxidase A	Homo sapiens	114-119
33339338-2	2020	We synthesized more than 60 analogues of harmine, either by direct modification of the alkaloid or by de novo synthesis of beta-carboline and related scaffolds aimed at learning about structure-activity relationships for inhibition of both DYRK1A and MAO-A, with the ultimate goal of separating desired DYRK1A inhibition from undesired MAO-A inhibition.	Harmine	41-48	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	240-246
33339338-2	2020	We synthesized more than 60 analogues of harmine, either by direct modification of the alkaloid or by de novo synthesis of beta-carboline and related scaffolds aimed at learning about structure-activity relationships for inhibition of both DYRK1A and MAO-A, with the ultimate goal of separating desired DYRK1A inhibition from undesired MAO-A inhibition.	Harmine	41-48	monoamine oxidase A	Homo sapiens	251-256
33339338-2	2020	We synthesized more than 60 analogues of harmine, either by direct modification of the alkaloid or by de novo synthesis of beta-carboline and related scaffolds aimed at learning about structure-activity relationships for inhibition of both DYRK1A and MAO-A, with the ultimate goal of separating desired DYRK1A inhibition from undesired MAO-A inhibition.	Harmine	41-48	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	303-309
33339338-2	2020	We synthesized more than 60 analogues of harmine, either by direct modification of the alkaloid or by de novo synthesis of beta-carboline and related scaffolds aimed at learning about structure-activity relationships for inhibition of both DYRK1A and MAO-A, with the ultimate goal of separating desired DYRK1A inhibition from undesired MAO-A inhibition.	Harmine	41-48	monoamine oxidase A	Homo sapiens	336-341
33339338-3	2020	Based on evidence from published crystal structures of harmine bound to each of these enzymes, we performed systematic structure modifications of harmine yielding DYRK1A-selective inhibitors characterized by small polar substituents at N-9 (which preserve DYRK1A inhibition and eliminate MAO-A inhibition) and beneficial residues at C-1 (methyl or chlorine).	Harmine	146-153	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	163-169
33316942-8	2020	Our results highlight the great potential of this approach for drug repurposing and suggest that harmine and piperlongumine or similar compounds might be useful in the clinic to overcome TRIB2-mediated therapy resistance in cancer patients.	Harmine	97-104	tribbles pseudokinase 2	Homo sapiens	187-192
32462403-13	2020	Furthermore, the pharmacological modulation of this protein by different inhibitors (harmine, curcumine, LDN192960, and ID-8) has enabled to clarify DYRK2 functionality.	Harmine	85-92	dual specificity tyrosine phosphorylation regulated kinase 2	Homo sapiens	149-154
32761352-0	2020	Human CYP2D6 in the Brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized CYP2D6 Transgenic Mice.	Harmine	48-55	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	6-12
32761352-0	2020	Human CYP2D6 in the Brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized CYP2D6 Transgenic Mice.	Harmine	48-55	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	103-109
32761352-3	2020	The beta-carboline harmine, which induces hypothermia and tremor, is metabolized by CYP2D6 to the non-hypothermic/non-tremorgenic harmol.	Harmine	19-26	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	84-90
32761352-4	2020	Transgenic mice (TG), expressing human CYP2D6 in addition to their endogenous mouse CYP2D, experience less harmine-induced hypothermia and tremor compared with wild-type mice (WT).	Harmine	107-114	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	39-45
32761352-4	2020	Transgenic mice (TG), expressing human CYP2D6 in addition to their endogenous mouse CYP2D, experience less harmine-induced hypothermia and tremor compared with wild-type mice (WT).	Harmine	107-114	cytochrome P450, 2d region	Mus musculus	39-44
32761352-5	2020	We first sought to elucidate the role of CYP2D in general within the brain in harmine-induced hypothermia and tremor severity.	Harmine	78-85	cytochrome P450, 2d region	Mus musculus	41-46
32761352-6	2020	A 4-h intracerebroventricular (ICV) pretreatment with the CYP2D inhibitor propranolol increased harmine-induced hypothermia and tremor in TG and increased harmine-induced hypothermia in WT.	Harmine	96-103	cytochrome P450, 2d region	Mus musculus	58-63
32761352-6	2020	A 4-h intracerebroventricular (ICV) pretreatment with the CYP2D inhibitor propranolol increased harmine-induced hypothermia and tremor in TG and increased harmine-induced hypothermia in WT.	Harmine	155-162	cytochrome P450, 2d region	Mus musculus	58-63
32761352-7	2020	We next sought to specifically demonstrate that human CYP2D6 expressed in TG brain altered harmine response severity.	Harmine	91-98	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
32761352-8	2020	A 24-h ICV propranolol pretreatment, which selectively and irreversibly inhibits human CYP2D6 in TG brain, increased harmine-induced hypothermia.	Harmine	117-124	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	87-93
32761352-10	2020	Human CYP2D6 activity in TG brain was sufficient in vivo to mitigate harmine-induced neurotoxicity.	Harmine	69-76	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	6-12
32807492-13	2020	These spheroids also revealed sensitizing potential of DYRK1A inhibitors tested in this study, including Harmine, INDY and L41.	Harmine	105-112	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	55-61
32380384-10	2020	Harmine, Clorgyline, Isatin, zonisamide and our title compound including are known with their competitive inhibitory activity on Human monoamine oxidase, commonly named MAO A and B.	Harmine	0-7	monoamine oxidase A	Homo sapiens	169-180
32425784-0	2020	Harmine Ameliorates Cognitive Impairment by Inhibiting NLRP3 Inflammasome Activation and Enhancing the BDNF/TrkB Signaling Pathway in STZ-Induced Diabetic Rats.	Harmine	0-7	NLR family, pyrin domain containing 3	Rattus norvegicus	55-60
32088835-3	2020	The monoamine oxidase A inhibitor drug harmine was suggested to have both antidepressant and anti-inflammatory properties and may, therefore, be a potential candidate for treatment of depression.	Harmine	39-46	monoamine oxidase A	Rattus norvegicus	4-23
32425784-0	2020	Harmine Ameliorates Cognitive Impairment by Inhibiting NLRP3 Inflammasome Activation and Enhancing the BDNF/TrkB Signaling Pathway in STZ-Induced Diabetic Rats.	Harmine	0-7	brain-derived neurotrophic factor	Rattus norvegicus	103-107
32425784-0	2020	Harmine Ameliorates Cognitive Impairment by Inhibiting NLRP3 Inflammasome Activation and Enhancing the BDNF/TrkB Signaling Pathway in STZ-Induced Diabetic Rats.	Harmine	0-7	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	108-112
32425784-7	2020	Further study showed that harmine inhibited NLRP3 inflammasome activation, as demonstrated by reduced NLRP3, ASC, cleaved caspase-1, IL-1beta, and IL-18 levels, in the cortex of harmine-treated rats with DM.	Harmine	26-33	NLR family, pyrin domain containing 3	Rattus norvegicus	44-49
32425784-7	2020	Further study showed that harmine inhibited NLRP3 inflammasome activation, as demonstrated by reduced NLRP3, ASC, cleaved caspase-1, IL-1beta, and IL-18 levels, in the cortex of harmine-treated rats with DM.	Harmine	26-33	NLR family, pyrin domain containing 3	Rattus norvegicus	102-107
32425784-7	2020	Further study showed that harmine inhibited NLRP3 inflammasome activation, as demonstrated by reduced NLRP3, ASC, cleaved caspase-1, IL-1beta, and IL-18 levels, in the cortex of harmine-treated rats with DM.	Harmine	26-33	PYD and CARD domain containing	Rattus norvegicus	109-112
32425784-7	2020	Further study showed that harmine inhibited NLRP3 inflammasome activation, as demonstrated by reduced NLRP3, ASC, cleaved caspase-1, IL-1beta, and IL-18 levels, in the cortex of harmine-treated rats with DM.	Harmine	26-33	caspase 1	Rattus norvegicus	122-131
32425784-7	2020	Further study showed that harmine inhibited NLRP3 inflammasome activation, as demonstrated by reduced NLRP3, ASC, cleaved caspase-1, IL-1beta, and IL-18 levels, in the cortex of harmine-treated rats with DM.	Harmine	26-33	interleukin 1 alpha	Rattus norvegicus	133-141
32425784-7	2020	Further study showed that harmine inhibited NLRP3 inflammasome activation, as demonstrated by reduced NLRP3, ASC, cleaved caspase-1, IL-1beta, and IL-18 levels, in the cortex of harmine-treated rats with DM.	Harmine	26-33	interleukin 18	Rattus norvegicus	147-152
32425784-7	2020	Further study showed that harmine inhibited NLRP3 inflammasome activation, as demonstrated by reduced NLRP3, ASC, cleaved caspase-1, IL-1beta, and IL-18 levels, in the cortex of harmine-treated rats with DM.	Harmine	178-185	NLR family, pyrin domain containing 3	Rattus norvegicus	44-49
32425784-9	2020	Moreover, we found that harmine treatment enhanced BDNF and phosphorylated TrkB levels in both the cortex of STZ-induced diabetic rats and HG-treated cells.	Harmine	24-31	brain-derived neurotrophic factor	Rattus norvegicus	51-55
32425784-9	2020	Moreover, we found that harmine treatment enhanced BDNF and phosphorylated TrkB levels in both the cortex of STZ-induced diabetic rats and HG-treated cells.	Harmine	24-31	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	75-79
32425784-10	2020	These data indicate that harmine mitigates cognitive impairment by inhibiting NLRP3 inflammasome activation and enhancing the BDNF/TrkB signaling pathway.	Harmine	25-32	NLR family, pyrin domain containing 3	Rattus norvegicus	78-83
32425784-10	2020	These data indicate that harmine mitigates cognitive impairment by inhibiting NLRP3 inflammasome activation and enhancing the BDNF/TrkB signaling pathway.	Harmine	25-32	brain-derived neurotrophic factor	Rattus norvegicus	126-130
32425784-10	2020	These data indicate that harmine mitigates cognitive impairment by inhibiting NLRP3 inflammasome activation and enhancing the BDNF/TrkB signaling pathway.	Harmine	25-32	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	131-135
32032735-8	2020	Treatment with another DYRK1A inhibitor, harmine, was capable of correcting neuronal CDKL5-dependent defects; moreover, DYRK1A levels were upregulated in primary Cdkl5-KO neurons in concomitance with increased phosphorylation of Tau, a well-accepted DYRK1A substrate.	Harmine	41-48	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	23-29
32032735-8	2020	Treatment with another DYRK1A inhibitor, harmine, was capable of correcting neuronal CDKL5-dependent defects; moreover, DYRK1A levels were upregulated in primary Cdkl5-KO neurons in concomitance with increased phosphorylation of Tau, a well-accepted DYRK1A substrate.	Harmine	41-48	cyclin-dependent kinase-like 5	Mus musculus	85-90
32032735-8	2020	Treatment with another DYRK1A inhibitor, harmine, was capable of correcting neuronal CDKL5-dependent defects; moreover, DYRK1A levels were upregulated in primary Cdkl5-KO neurons in concomitance with increased phosphorylation of Tau, a well-accepted DYRK1A substrate.	Harmine	41-48	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	120-126
32032735-8	2020	Treatment with another DYRK1A inhibitor, harmine, was capable of correcting neuronal CDKL5-dependent defects; moreover, DYRK1A levels were upregulated in primary Cdkl5-KO neurons in concomitance with increased phosphorylation of Tau, a well-accepted DYRK1A substrate.	Harmine	41-48	cyclin-dependent kinase-like 5	Mus musculus	162-167
32032735-8	2020	Treatment with another DYRK1A inhibitor, harmine, was capable of correcting neuronal CDKL5-dependent defects; moreover, DYRK1A levels were upregulated in primary Cdkl5-KO neurons in concomitance with increased phosphorylation of Tau, a well-accepted DYRK1A substrate.	Harmine	41-48	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	120-126
32340326-1	2020	Recently, we have shown that harmine induces beta-cell proliferation both in vitro and in vivo, mediated via the DYRK1A-NFAT pathway.	Harmine	29-36	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	113-119
32340326-2	2020	We explore structure-activity relationships of the 7-position of harmine for both DYRK1A kinase inhibition and beta-cell proliferation based on our related previous structure-activity relationship studies of harmine in the context of diabetes and beta-cell specific targeting strategies.	Harmine	65-72	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	82-88
32340326-5	2020	The DYRK1A inhibitor, compound 1-2b, induced beta-cell proliferation half that of harmine at three times higher concentration.	Harmine	82-89	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	4-10
31821176-1	2020	Small molecule inhibitors of Dual Specificity, Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A), including harmine and others, are able to drive human beta cell regeneration.	Harmine	112-119	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	29-91
32003560-0	2020	Synthesis and Biological Validation of a Harmine-based, Central Nervous System (CNS)-Avoidant, Selective, Human beta-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.	Harmine	41-48	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	197-203
32003560-1	2020	Recently, our group identified that harmine is able to induce beta-cell proliferation both in vitro and in vivo, mediated via the DYRK1A-NFAT pathway.	Harmine	36-43	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	130-136
32003560-2	2020	Since, harmine suffers from lack of selectivity, both against other kinases and CNS off-targets, therefore, we sought to expand structure-activity relationships for harmine"s DYRK1A activity, to enhance selectivity for off-targets, while retaining human beta-cell proliferation activity.	Harmine	165-172	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	175-181
31901541-5	2020	The Notch, Wnt, Hedgehog and TGF-beta pathways mainly played vital roles in coping with harmine exposure in pupae stage, while the Hippo, Hedgehog and TGF-beta elements were involved in the sex differences.	Harmine	88-95	Wnt oncogene analog 2	Drosophila melanogaster	11-14
31901541-5	2020	The Notch, Wnt, Hedgehog and TGF-beta pathways mainly played vital roles in coping with harmine exposure in pupae stage, while the Hippo, Hedgehog and TGF-beta elements were involved in the sex differences.	Harmine	88-95	hedgehog	Drosophila melanogaster	16-24
31901541-5	2020	The Notch, Wnt, Hedgehog and TGF-beta pathways mainly played vital roles in coping with harmine exposure in pupae stage, while the Hippo, Hedgehog and TGF-beta elements were involved in the sex differences.	Harmine	88-95	decapentaplegic	Drosophila melanogaster	29-37
31901541-6	2020	Notch, Hippo, Hedgehog, Dpp and Armadillo were proved to be suppressed in the developmental inhibition with fly mutants, while Numb and Punt were increased by harmine.	Harmine	159-166	numb	Drosophila melanogaster	127-131
30909826-1	2020	The work highlighted interaction of harmalol, harmaline and harmine with human serum albumin by biophysical and biochemical assays.	Harmine	60-67	albumin	Homo sapiens	79-92
31821176-1	2020	Small molecule inhibitors of Dual Specificity, Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A), including harmine and others, are able to drive human beta cell regeneration.	Harmine	112-119	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	93-99
31821176-6	2020	Importantly, other potential kinases, such as the CLK and the GSK3 families, are excluded as important harmine targets.	Harmine	103-110	CDC like kinase 1	Homo sapiens	50-53
31776330-8	2019	Finally, direct inhibition of TWIST1 by a small-molecule compound harmine was paralleled by blockade of EndMT in cultured cells and liver fibrosis in mice.	Harmine	66-73	twist basic helix-loop-helix transcription factor 1	Mus musculus	30-36
30910851-0	2019	Harmine suppresses bladder tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.	Harmine	0-7	kinase insert domain receptor	Homo sapiens	55-100
31572127-10	2019	Knockdown of DYRK1A expression or treatment of the DYRK1A inhibitor harmine attenuated miR-204-5p-induced increase in protein expression of phospho-alpha-Syn or phospho-tau, ER stress, autophagy impairment, and activation of JNK-mediated apoptotic pathway in SH-SY5Y dopaminergic cells or primary cultured dopaminergic neurons.	Harmine	68-75	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	51-57
31572127-10	2019	Knockdown of DYRK1A expression or treatment of the DYRK1A inhibitor harmine attenuated miR-204-5p-induced increase in protein expression of phospho-alpha-Syn or phospho-tau, ER stress, autophagy impairment, and activation of JNK-mediated apoptotic pathway in SH-SY5Y dopaminergic cells or primary cultured dopaminergic neurons.	Harmine	68-75	membrane associated ring-CH-type finger 8	Homo sapiens	87-90
31572127-10	2019	Knockdown of DYRK1A expression or treatment of the DYRK1A inhibitor harmine attenuated miR-204-5p-induced increase in protein expression of phospho-alpha-Syn or phospho-tau, ER stress, autophagy impairment, and activation of JNK-mediated apoptotic pathway in SH-SY5Y dopaminergic cells or primary cultured dopaminergic neurons.	Harmine	68-75	synuclein alpha	Homo sapiens	148-157
31572127-10	2019	Knockdown of DYRK1A expression or treatment of the DYRK1A inhibitor harmine attenuated miR-204-5p-induced increase in protein expression of phospho-alpha-Syn or phospho-tau, ER stress, autophagy impairment, and activation of JNK-mediated apoptotic pathway in SH-SY5Y dopaminergic cells or primary cultured dopaminergic neurons.	Harmine	68-75	mitogen-activated protein kinase 8	Homo sapiens	225-228
31198408-7	2019	Results: The natural compound harmine, isolated from the plant Peganum harmala, was found to suppress the Muv phenotype of let-60(n1046gf).	Harmine	30-37	Ras protein let-60	Caenorhabditis elegans	123-129
31198408-8	2019	In addition, harmine targets the hyper-activation of the Ras/MAPK pathway specifically caused by overexpression or mutated forms of LET-60/Ras and its immediate downstream molecule LIN-45/Raf.	Harmine	13-20	Ras protein let-60	Caenorhabditis elegans	132-138
31198408-8	2019	In addition, harmine targets the hyper-activation of the Ras/MAPK pathway specifically caused by overexpression or mutated forms of LET-60/Ras and its immediate downstream molecule LIN-45/Raf.	Harmine	13-20	Raf homolog serine/threonine-protein kinase	Caenorhabditis elegans	181-187
31454149-3	2019	Meanwhile, the DYRK1A inhibitor harmine could suppress the proliferation of NSCLC cells compared to that of the control.	Harmine	32-39	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	15-21
31454149-7	2019	Meanwhile, harmine could also regulate the STAT3/EGFR/Met signalling pathway in human NSCLC cells.	Harmine	11-18	signal transducer and activator of transcription 3	Homo sapiens	43-48
31454149-7	2019	Meanwhile, harmine could also regulate the STAT3/EGFR/Met signalling pathway in human NSCLC cells.	Harmine	11-18	epidermal growth factor receptor	Homo sapiens	49-53
31454149-10	2019	In addition, harmine could enhance the anti-NSCLC activity of AZD9291 by modulating STAT3 pathway.	Harmine	13-20	signal transducer and activator of transcription 3	Homo sapiens	84-89
31154274-1	2019	BACKGROUND: beta-Carboline alkaloid harmine (HAR) and harmaline (HAL) are monoamine oxidase (MAO) and acetylcholinesterase (AChE) inhibitors.	Harmine	36-43	acetylcholinesterase	Rattus norvegicus	102-122
31154274-1	2019	BACKGROUND: beta-Carboline alkaloid harmine (HAR) and harmaline (HAL) are monoamine oxidase (MAO) and acetylcholinesterase (AChE) inhibitors.	Harmine	36-43	acetylcholinesterase	Rattus norvegicus	124-128
31154274-1	2019	BACKGROUND: beta-Carboline alkaloid harmine (HAR) and harmaline (HAL) are monoamine oxidase (MAO) and acetylcholinesterase (AChE) inhibitors.	Harmine	45-48	acetylcholinesterase	Rattus norvegicus	102-122
31154274-1	2019	BACKGROUND: beta-Carboline alkaloid harmine (HAR) and harmaline (HAL) are monoamine oxidase (MAO) and acetylcholinesterase (AChE) inhibitors.	Harmine	45-48	acetylcholinesterase	Rattus norvegicus	124-128
31048127-0	2019	Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation.	Harmine	17-24	synuclein alpha	Homo sapiens	49-64
31048127-14	2019	PKA inhibitor blocked the effects of harmine in activating UPS, up regulating PSMD1 and promoting <alpha>-syn degradation, indicating that harmine enhances UPS function via PKA activation.	Harmine	37-44	proteasome 26S subunit, non-ATPase 1	Homo sapiens	78-83
31354292-7	2019	The AKT/mTOR pathway is involved in mechanisms of gemcitabine resistance in pancreatic cancer cells, our data demonstrated that harmine plus gemcitabine significantly suppressed the AKT/mTOR signaling pathway.	Harmine	128-135	AKT serine/threonine kinase 1	Homo sapiens	4-7
31354292-7	2019	The AKT/mTOR pathway is involved in mechanisms of gemcitabine resistance in pancreatic cancer cells, our data demonstrated that harmine plus gemcitabine significantly suppressed the AKT/mTOR signaling pathway.	Harmine	128-135	mechanistic target of rapamycin kinase	Homo sapiens	8-12
31354292-7	2019	The AKT/mTOR pathway is involved in mechanisms of gemcitabine resistance in pancreatic cancer cells, our data demonstrated that harmine plus gemcitabine significantly suppressed the AKT/mTOR signaling pathway.	Harmine	128-135	AKT serine/threonine kinase 1	Homo sapiens	182-185
31354292-7	2019	The AKT/mTOR pathway is involved in mechanisms of gemcitabine resistance in pancreatic cancer cells, our data demonstrated that harmine plus gemcitabine significantly suppressed the AKT/mTOR signaling pathway.	Harmine	128-135	mechanistic target of rapamycin kinase	Homo sapiens	186-190
30910851-6	2019	To further explore the pharmacological activities of harmine, we tested harmine"s influence on blood vessel formation and found that harmine effectively blocked the microvessel sprouting in rat aortic ring assay when stimulated by vascular endothelial growth factor (VEGF).	Harmine	53-60	vascular endothelial growth factor A	Rattus norvegicus	231-265
30910851-6	2019	To further explore the pharmacological activities of harmine, we tested harmine"s influence on blood vessel formation and found that harmine effectively blocked the microvessel sprouting in rat aortic ring assay when stimulated by vascular endothelial growth factor (VEGF).	Harmine	72-79	vascular endothelial growth factor A	Rattus norvegicus	231-265
30910851-6	2019	To further explore the pharmacological activities of harmine, we tested harmine"s influence on blood vessel formation and found that harmine effectively blocked the microvessel sprouting in rat aortic ring assay when stimulated by vascular endothelial growth factor (VEGF).	Harmine	72-79	vascular endothelial growth factor A	Rattus norvegicus	231-265
30910851-8	2019	Moreover, harmine induced bladder cancer cell apoptosis through triggering the caspase-dependent apoptotic pathway and the downstream vascular endothelial growth factor receptor 2 (VEGFR2) kinase pathway was down-regulated, thus suppressing tumor development signals.	Harmine	10-17	kinase insert domain receptor	Homo sapiens	134-179
30910851-8	2019	Moreover, harmine induced bladder cancer cell apoptosis through triggering the caspase-dependent apoptotic pathway and the downstream vascular endothelial growth factor receptor 2 (VEGFR2) kinase pathway was down-regulated, thus suppressing tumor development signals.	Harmine	10-17	kinase insert domain receptor	Homo sapiens	181-187
30910851-9	2019	Herein, our study demonstrated that natural product harmine might have potential in curing human bladder tumor because of its pharmacological function on tumor angiogenesis, trigged by VEGFR2 signaling pathways.	Harmine	52-59	kinase insert domain receptor	Homo sapiens	185-191
30716318-0	2019	Harmine mitigates LPS-induced acute kidney injury through inhibition of the TLR4-NF-kappaB/NLRP3 inflammasome signalling pathway in mice.	Harmine	0-7	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	81-90
30716318-0	2019	Harmine mitigates LPS-induced acute kidney injury through inhibition of the TLR4-NF-kappaB/NLRP3 inflammasome signalling pathway in mice.	Harmine	0-7	NLR family, pyrin domain containing 3	Mus musculus	91-96
30716318-0	2019	Harmine mitigates LPS-induced acute kidney injury through inhibition of the TLR4-NF-kappaB/NLRP3 inflammasome signalling pathway in mice.	Harmine	0-7	toll-like receptor 4	Mus musculus	76-80
30716318-7	2019	The results showed that pretreatment with harmine (25 or 50 mg/kg) markedly alleviated kidney injury by reducing the release of kidney biomarkers and inflammatory mediators and the formation of malondialdehyde (MDA) and myeloperoxidase (MPO) while increasing superoxide dismutase (SOD) and glutathione (GSH) activities and improving renal histopathological changes.	Harmine	42-49	myeloperoxidase	Mus musculus	220-235
30716318-7	2019	The results showed that pretreatment with harmine (25 or 50 mg/kg) markedly alleviated kidney injury by reducing the release of kidney biomarkers and inflammatory mediators and the formation of malondialdehyde (MDA) and myeloperoxidase (MPO) while increasing superoxide dismutase (SOD) and glutathione (GSH) activities and improving renal histopathological changes.	Harmine	42-49	myeloperoxidase	Mus musculus	237-240
30716318-8	2019	In addition, immunohistochemistry staining and western blot analysis indicated that harmine treatment suppressed the expression of toll-like receptor 4 (TLR4) and the phosphorylation of nuclear factor-kappa B (NF-kappaB) p65 and inhibitor of kappaBalpha (IkappaBalpha) while inhibiting the expression of NLRP3, caspase-1 and interleukin-1beta (IL-1beta).	Harmine	84-91	toll-like receptor 4	Mus musculus	131-151
30716318-8	2019	In addition, immunohistochemistry staining and western blot analysis indicated that harmine treatment suppressed the expression of toll-like receptor 4 (TLR4) and the phosphorylation of nuclear factor-kappa B (NF-kappaB) p65 and inhibitor of kappaBalpha (IkappaBalpha) while inhibiting the expression of NLRP3, caspase-1 and interleukin-1beta (IL-1beta).	Harmine	84-91	toll-like receptor 4	Mus musculus	153-157
30716318-8	2019	In addition, immunohistochemistry staining and western blot analysis indicated that harmine treatment suppressed the expression of toll-like receptor 4 (TLR4) and the phosphorylation of nuclear factor-kappa B (NF-kappaB) p65 and inhibitor of kappaBalpha (IkappaBalpha) while inhibiting the expression of NLRP3, caspase-1 and interleukin-1beta (IL-1beta).	Harmine	84-91	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	186-208
30716318-8	2019	In addition, immunohistochemistry staining and western blot analysis indicated that harmine treatment suppressed the expression of toll-like receptor 4 (TLR4) and the phosphorylation of nuclear factor-kappa B (NF-kappaB) p65 and inhibitor of kappaBalpha (IkappaBalpha) while inhibiting the expression of NLRP3, caspase-1 and interleukin-1beta (IL-1beta).	Harmine	84-91	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	210-219
30716318-8	2019	In addition, immunohistochemistry staining and western blot analysis indicated that harmine treatment suppressed the expression of toll-like receptor 4 (TLR4) and the phosphorylation of nuclear factor-kappa B (NF-kappaB) p65 and inhibitor of kappaBalpha (IkappaBalpha) while inhibiting the expression of NLRP3, caspase-1 and interleukin-1beta (IL-1beta).	Harmine	84-91	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	221-224
30716318-8	2019	In addition, immunohistochemistry staining and western blot analysis indicated that harmine treatment suppressed the expression of toll-like receptor 4 (TLR4) and the phosphorylation of nuclear factor-kappa B (NF-kappaB) p65 and inhibitor of kappaBalpha (IkappaBalpha) while inhibiting the expression of NLRP3, caspase-1 and interleukin-1beta (IL-1beta).	Harmine	84-91	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	255-267
30716318-8	2019	In addition, immunohistochemistry staining and western blot analysis indicated that harmine treatment suppressed the expression of toll-like receptor 4 (TLR4) and the phosphorylation of nuclear factor-kappa B (NF-kappaB) p65 and inhibitor of kappaBalpha (IkappaBalpha) while inhibiting the expression of NLRP3, caspase-1 and interleukin-1beta (IL-1beta).	Harmine	84-91	NLR family, pyrin domain containing 3	Mus musculus	304-309
30716318-8	2019	In addition, immunohistochemistry staining and western blot analysis indicated that harmine treatment suppressed the expression of toll-like receptor 4 (TLR4) and the phosphorylation of nuclear factor-kappa B (NF-kappaB) p65 and inhibitor of kappaBalpha (IkappaBalpha) while inhibiting the expression of NLRP3, caspase-1 and interleukin-1beta (IL-1beta).	Harmine	84-91	caspase 1	Mus musculus	311-320
30716318-8	2019	In addition, immunohistochemistry staining and western blot analysis indicated that harmine treatment suppressed the expression of toll-like receptor 4 (TLR4) and the phosphorylation of nuclear factor-kappa B (NF-kappaB) p65 and inhibitor of kappaBalpha (IkappaBalpha) while inhibiting the expression of NLRP3, caspase-1 and interleukin-1beta (IL-1beta).	Harmine	84-91	interleukin 1 beta	Mus musculus	325-342
30716318-8	2019	In addition, immunohistochemistry staining and western blot analysis indicated that harmine treatment suppressed the expression of toll-like receptor 4 (TLR4) and the phosphorylation of nuclear factor-kappa B (NF-kappaB) p65 and inhibitor of kappaBalpha (IkappaBalpha) while inhibiting the expression of NLRP3, caspase-1 and interleukin-1beta (IL-1beta).	Harmine	84-91	interleukin 1 beta	Mus musculus	344-352
30716318-10	2019	The involved underlying mechanisms of harmine in LPS-induced acute kidney injury might be related to inhibition of the TLR4-NF-kappaB pathway and NLRP3 inflammasome pathway.	Harmine	38-45	toll-like receptor 4	Mus musculus	119-123
30716318-10	2019	The involved underlying mechanisms of harmine in LPS-induced acute kidney injury might be related to inhibition of the TLR4-NF-kappaB pathway and NLRP3 inflammasome pathway.	Harmine	38-45	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	124-133
30716318-10	2019	The involved underlying mechanisms of harmine in LPS-induced acute kidney injury might be related to inhibition of the TLR4-NF-kappaB pathway and NLRP3 inflammasome pathway.	Harmine	38-45	NLR family, pyrin domain containing 3	Mus musculus	146-151
29802995-7	2018	We also examined the effect of severe environmental stress including heat shock, osmotic shock, and exposure to the alkaloid drug harmine on CLK1 alternative splicing in DU145 prostate cancer cells.	Harmine	130-137	CDC like kinase 1	Homo sapiens	141-145
30171258-8	2019	We demonstrated that genetic silencing of TWIST1 or treatment with the TWIST1 inhibitor, harmine, resulted in growth inhibition and apoptosis in EGFR-mutant NSCLC.	Harmine	89-96	twist family bHLH transcription factor 1	Homo sapiens	71-77
30171258-8	2019	We demonstrated that genetic silencing of TWIST1 or treatment with the TWIST1 inhibitor, harmine, resulted in growth inhibition and apoptosis in EGFR-mutant NSCLC.	Harmine	89-96	epidermal growth factor receptor	Homo sapiens	145-149
29788780-4	2018	Conclusion & future perspective: The current study delineates the structural requirements for MAO-A selectivity and such information may be helpful in designing selective analogs for kinase, DYRK1A and harmine-based cytotoxics without apparent MAO enzyme inhibition.	Harmine	206-213	monoamine oxidase A	Homo sapiens	98-103
29423903-0	2018	[11C]Harmine Binding to Brain Monoamine Oxidase A: Test-Retest Properties and Noninvasive Quantification.	Harmine	5-12	monoamine oxidase A	Homo sapiens	30-49
29977157-0	2018	Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma.	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	11-69
29977157-0	2018	Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma.	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	71-75
29977157-3	2018	Harmine is capable of blocking the activities of dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) family proteins and mitogen-activated protein kinase.	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	49-107
29977157-3	2018	Harmine is capable of blocking the activities of dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) family proteins and mitogen-activated protein kinase.	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	109-113
29977157-6	2018	The anti-cancer properties of harmine were examined by RealTime-Glo MT cell viability assays, caspase activity assays, PARP cleavage using Western blot analysis, and flow cytometry-based Annexin V detection.	Harmine	30-37	caspase 9	Homo sapiens	94-101
29977157-6	2018	The anti-cancer properties of harmine were examined by RealTime-Glo MT cell viability assays, caspase activity assays, PARP cleavage using Western blot analysis, and flow cytometry-based Annexin V detection.	Harmine	30-37	collagen type XI alpha 2 chain	Homo sapiens	119-123
29977157-6	2018	The anti-cancer properties of harmine were examined by RealTime-Glo MT cell viability assays, caspase activity assays, PARP cleavage using Western blot analysis, and flow cytometry-based Annexin V detection.	Harmine	30-37	annexin A5	Homo sapiens	187-196
29977157-7	2018	A molecular interaction model of harmine bound to the DYRK2 family kinase was generated by computational docking using X-ray structures.	Harmine	33-40	dual specificity tyrosine phosphorylation regulated kinase 2	Homo sapiens	54-59
29977157-10	2018	Exposure of these NB cell lines to 100 muM of harmine resulted in caspase-3/7 and caspase-9 activation as well as caspase-mediated PARP cleavage and Annexin V-positive stained cells, as early as 24 h after treatment, clearly suggesting apoptosis induction, especially in MYCN-amplified cell lines.	Harmine	46-53	caspase 9	Homo sapiens	82-91
29977157-10	2018	Exposure of these NB cell lines to 100 muM of harmine resulted in caspase-3/7 and caspase-9 activation as well as caspase-mediated PARP cleavage and Annexin V-positive stained cells, as early as 24 h after treatment, clearly suggesting apoptosis induction, especially in MYCN-amplified cell lines.	Harmine	46-53	caspase 9	Homo sapiens	66-73
29977157-10	2018	Exposure of these NB cell lines to 100 muM of harmine resulted in caspase-3/7 and caspase-9 activation as well as caspase-mediated PARP cleavage and Annexin V-positive stained cells, as early as 24 h after treatment, clearly suggesting apoptosis induction, especially in MYCN-amplified cell lines.	Harmine	46-53	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	271-275
29977157-12	2018	Conclusion: Harmine is a known inhibitor of DYRK family kinases.	Harmine	12-19	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	44-48
29977157-14	2018	The patient results support our hypothesis that DYRK inhibition by harmine and the subsequent triggering of caspase-mediated apoptosis might present a novel approach to NB therapy.	Harmine	67-74	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	48-52
29428472-0	2018	A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.	Harmine	8-15	histone deacetylase 9	Homo sapiens	127-146
29634919-4	2018	In the present study, we determined the crystal structure of the mature form of human DYRK3 in complex with harmine, an ATP competitive inhibitor.	Harmine	108-115	dual specificity tyrosine phosphorylation regulated kinase 3	Homo sapiens	86-91
29755345-0	2018	Analogous beta-Carboline Alkaloids Harmaline and Harmine Ameliorate Scopolamine-Induced Cognition Dysfunction by Attenuating Acetylcholinesterase Activity, Oxidative Stress, and Inflammation in Mice.	Harmine	49-56	acetylcholinesterase	Mus musculus	125-145
29755345-1	2018	The analogous beta-carboline alkaloids, harmaline (HAL) and harmine (HAR), possess a variety of biological properties, including acetylcholinesterase (AChE) inhibitory activity, antioxidant, anti-inflammatory, and many others, and have great potential for treating Alzheimer"s disease (AD).	Harmine	60-67	acetylcholinesterase	Mus musculus	129-149
29755345-1	2018	The analogous beta-carboline alkaloids, harmaline (HAL) and harmine (HAR), possess a variety of biological properties, including acetylcholinesterase (AChE) inhibitory activity, antioxidant, anti-inflammatory, and many others, and have great potential for treating Alzheimer"s disease (AD).	Harmine	60-67	acetylcholinesterase	Mus musculus	151-155
29755345-1	2018	The analogous beta-carboline alkaloids, harmaline (HAL) and harmine (HAR), possess a variety of biological properties, including acetylcholinesterase (AChE) inhibitory activity, antioxidant, anti-inflammatory, and many others, and have great potential for treating Alzheimer"s disease (AD).	Harmine	69-72	acetylcholinesterase	Mus musculus	129-149
29755345-1	2018	The analogous beta-carboline alkaloids, harmaline (HAL) and harmine (HAR), possess a variety of biological properties, including acetylcholinesterase (AChE) inhibitory activity, antioxidant, anti-inflammatory, and many others, and have great potential for treating Alzheimer"s disease (AD).	Harmine	69-72	acetylcholinesterase	Mus musculus	151-155
29428472-1	2018	This study aims to design and synthesize a novel harmine derivative N-(4-(hydroxycarbamoyl) benzyl)-1-(4-methoxyphenyl)-9H-pyrido [3,4-b]indole-3-carboxamide (HBC) as histone deacetylase (HDAC) inhibitor, and evaluate its antitumor activities and anti-metastasis mechanism.	Harmine	49-56	histone deacetylase 9	Homo sapiens	167-186
29428472-1	2018	This study aims to design and synthesize a novel harmine derivative N-(4-(hydroxycarbamoyl) benzyl)-1-(4-methoxyphenyl)-9H-pyrido [3,4-b]indole-3-carboxamide (HBC) as histone deacetylase (HDAC) inhibitor, and evaluate its antitumor activities and anti-metastasis mechanism.	Harmine	49-56	histone deacetylase 9	Homo sapiens	188-192
29428472-7	2018	These results demonstrate that novel harmine-based HDAC inhibitor HBC not only exhibited selective HDAC1/6 inhibitory activity and significant in vitro and in vivo antitumor activity, but also possessed DNA binding effect, apoptosis induction, cell cycle arrest effects, and potent anti-metastasis mechanisms, which may hold great promise as therapeutic agent targeting HDAC1/6 for the intervention of human cancers.	Harmine	37-44	histone deacetylase 9	Homo sapiens	51-55
29428472-7	2018	These results demonstrate that novel harmine-based HDAC inhibitor HBC not only exhibited selective HDAC1/6 inhibitory activity and significant in vitro and in vivo antitumor activity, but also possessed DNA binding effect, apoptosis induction, cell cycle arrest effects, and potent anti-metastasis mechanisms, which may hold great promise as therapeutic agent targeting HDAC1/6 for the intervention of human cancers.	Harmine	37-44	histone deacetylase 1	Homo sapiens	99-104
29428472-7	2018	These results demonstrate that novel harmine-based HDAC inhibitor HBC not only exhibited selective HDAC1/6 inhibitory activity and significant in vitro and in vivo antitumor activity, but also possessed DNA binding effect, apoptosis induction, cell cycle arrest effects, and potent anti-metastasis mechanisms, which may hold great promise as therapeutic agent targeting HDAC1/6 for the intervention of human cancers.	Harmine	37-44	histone deacetylase 1	Homo sapiens	99-106
29721090-4	2018	METHODS: The impact of harmine on osteoclastogenesis of RANKL-stimulated RAW264.7 cells was verified by gene expression analysis and tartrate-resistant acid phosphatase (TRAP) staining.	Harmine	23-30	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	56-61
29721090-11	2018	RESULTS: Exposure of RANKL-stimulated RAW264.7 cells to harmine enhanced the formation of preosteoclasts and the production of PDGF-BB.	Harmine	56-63	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	21-26
29721090-12	2018	Harmine augmented the ability of RANKL-stimulated RAW264.7 cells to promote angiogenesis of endothelial cells, whereas the effect was blocked by PDGF-BB inhibition.	Harmine	0-7	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	33-38
29253570-0	2018	Harmine promotes molar root development via SMAD1/5/8 phosphorylation.	Harmine	0-7	SMAD family member 1	Homo sapiens	44-51
29179659-7	2018	This phenotype was confirmed with chemical inhibition of DYRK1A using harmine and with primary HPCs cultured as liver organoids.	Harmine	70-77	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	57-63
29223449-9	2018	The active compound was isolated by bio-guided purification using thin layer chromatography (TLC) and identified by GC-MS and HPLC-DAD-ESI-MSn as harmine.	Harmine	146-153	moesin	Homo sapiens	139-142
29510387-11	2018	Mechanistically, in Harmine-treated NSCLC cells, RECK expression and its downstream signaling cascade were dramatically activated.	Harmine	20-27	reversion-inducing-cysteine-rich protein with kazal motifs	Mus musculus	49-53
29510387-13	2018	CONCLUSION: These findings identify Harmine as a promising activator of RECK signaling for metastatic NSCLC treatment.	Harmine	36-43	reversion-inducing-cysteine-rich protein with kazal motifs	Mus musculus	72-76
28851812-3	2017	Characterization of the top ranked candidates from the unbiased screen revealed that harmine, a harmala alkaloid, inhibited multiple TWIST1 functions, including single-cell dissemination, suppression of normal branching in 3D epithelial culture, and proliferation of oncogene driver-defined NSCLC cells.	Harmine	85-92	twist family bHLH transcription factor 1	Homo sapiens	133-139
29075061-0	2017	Harmine, a Novel DNA Methyltransferase 1 Inhibitor in the Leukemia Cell Line.	Harmine	0-7	DNA methyltransferase 1	Homo sapiens	17-40
29075061-4	2017	This study aimed to evaluate the effect of Harmine on DNMT1 (DNA methyl transferase 1) expression in a leukemic cell line.	Harmine	43-50	DNA methyltransferase 1	Homo sapiens	54-59
29075061-4	2017	This study aimed to evaluate the effect of Harmine on DNMT1 (DNA methyl transferase 1) expression in a leukemic cell line.	Harmine	43-50	DNA methyltransferase 1	Homo sapiens	61-85
29075061-9	2017	Anti proliferative doses of Harmine, has suppressed DNMT1 gene in NB4 cell line.	Harmine	28-35	DNA methyltransferase 1	Homo sapiens	52-57
28851812-4	2017	Harmine treatment phenocopied genetic loss of TWIST1 by inducing oncogene-induced senescence or apoptosis.	Harmine	0-7	twist family bHLH transcription factor 1	Homo sapiens	46-52
28851812-6	2017	As dimerization is critical for TWIST1 function and stability, the effect of harmine on specific TWIST1 dimers was examined.	Harmine	77-84	twist family bHLH transcription factor 1	Homo sapiens	97-103
28851812-8	2017	Harmine preferentially promoted degradation of the TWIST1-E2A heterodimer compared with the TWIST-TWIST1 homodimer, and targeting the TWIST1-E2A heterodimer was required for harmine cytotoxicity.	Harmine	0-7	twist family bHLH transcription factor 1	Homo sapiens	51-57
28851812-9	2017	Finally, harmine had activity in both transgenic and patient-derived xenograft mouse models of KRAS-mutant NSCLC.	Harmine	9-16	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	95-99
28851812-10	2017	These studies identified harmine as a first-in-class TWIST1 inhibitor with marked anti-tumor activity in oncogene-driven NSCLC including EGFR mutant, KRAS mutant and MET altered NSCLC.Implications: TWIST1 is required for oncogene-driven NSCLC tumorigenesis and EMT; thus, harmine and its analogues/derivatives represent a novel therapeutic strategy to treat oncogene-driven NSCLC as well as other solid tumor malignancies.	Harmine	25-32	twist family bHLH transcription factor 1	Homo sapiens	53-59
28851812-10	2017	These studies identified harmine as a first-in-class TWIST1 inhibitor with marked anti-tumor activity in oncogene-driven NSCLC including EGFR mutant, KRAS mutant and MET altered NSCLC.Implications: TWIST1 is required for oncogene-driven NSCLC tumorigenesis and EMT; thus, harmine and its analogues/derivatives represent a novel therapeutic strategy to treat oncogene-driven NSCLC as well as other solid tumor malignancies.	Harmine	25-32	epidermal growth factor receptor	Homo sapiens	137-141
28851812-10	2017	These studies identified harmine as a first-in-class TWIST1 inhibitor with marked anti-tumor activity in oncogene-driven NSCLC including EGFR mutant, KRAS mutant and MET altered NSCLC.Implications: TWIST1 is required for oncogene-driven NSCLC tumorigenesis and EMT; thus, harmine and its analogues/derivatives represent a novel therapeutic strategy to treat oncogene-driven NSCLC as well as other solid tumor malignancies.	Harmine	25-32	KRAS proto-oncogene, GTPase	Homo sapiens	150-154
28851812-10	2017	These studies identified harmine as a first-in-class TWIST1 inhibitor with marked anti-tumor activity in oncogene-driven NSCLC including EGFR mutant, KRAS mutant and MET altered NSCLC.Implications: TWIST1 is required for oncogene-driven NSCLC tumorigenesis and EMT; thus, harmine and its analogues/derivatives represent a novel therapeutic strategy to treat oncogene-driven NSCLC as well as other solid tumor malignancies.	Harmine	25-32	twist family bHLH transcription factor 1	Homo sapiens	198-204
28031411-8	2017	Inhibition of Dyrk1A activity using pharmacologic agents Harmine and INDY compromises viability of spheroids and blocks DREAM assembly.	Harmine	57-64	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	14-20
28871225-7	2017	However, when given MK571 and probenecid (the typical MRP2 inhibitor), the PappAB of harmine was increased (1.62- and 1.27-folds), and the efflux ratio was decreased from 1.59 to 0.98 and from 1.59 to 1.19, respectively.	Harmine	85-92	ATP binding cassette subfamily C member 2	Homo sapiens	54-58
28871225-8	2017	In addition, the uptake ratio of harmine at 1 muM was >2.65 in the membrane vesicles expressing human MRP2.	Harmine	33-40	ATP binding cassette subfamily C member 2	Homo sapiens	105-109
28871225-9	2017	Furthermore, harmine could slightly up-regulate the expression of MRP2, which implying harmine might be the substrate of MRP2.	Harmine	13-20	ATP binding cassette subfamily C member 2	Homo sapiens	66-70
28871225-9	2017	Furthermore, harmine could slightly up-regulate the expression of MRP2, which implying harmine might be the substrate of MRP2.	Harmine	13-20	ATP binding cassette subfamily C member 2	Homo sapiens	121-125
28871225-9	2017	Furthermore, harmine could slightly up-regulate the expression of MRP2, which implying harmine might be the substrate of MRP2.	Harmine	87-94	ATP binding cassette subfamily C member 2	Homo sapiens	66-70
28871225-9	2017	Furthermore, harmine could slightly up-regulate the expression of MRP2, which implying harmine might be the substrate of MRP2.	Harmine	87-94	ATP binding cassette subfamily C member 2	Homo sapiens	121-125
28871225-13	2017	MRP2 but MDR1 or BCRP might be involved in the transport of harmine.	Harmine	60-67	ATP binding cassette subfamily C member 2	Homo sapiens	0-4
28871225-13	2017	MRP2 but MDR1 or BCRP might be involved in the transport of harmine.	Harmine	60-67	ATP binding cassette subfamily B member 1	Homo sapiens	9-13
28871225-13	2017	MRP2 but MDR1 or BCRP might be involved in the transport of harmine.	Harmine	60-67	BCR pseudogene 1	Homo sapiens	17-21
28871225-15	2017	All these findings suggested that harmine not only appears be an MRP2 substrate, but also possesses weak metabolic stability, and eventually leads to a low oral bioavailability.	Harmine	34-41	ATP binding cassette subfamily C member 2	Homo sapiens	65-69
28314119-8	2017	Screening of a set of harmala alkaloids identified harmine as a potential neurotrophic molecule that significantly stimulated NGF-induced neurite outgrowth in the NS-1 cells.	Harmine	51-58	nerve growth factor	Rattus norvegicus	126-129
28901502-8	2017	Further study showed that harmine inhibited not only the basal phosphorylation level of extra-cellular signal-regulated kinase 1/2 (ERK1/2) and cyclic adenosine monophosphate response element-binding protein (CREB) but also EGF-induced ERK1/2 and CREB phosphorylation.	Harmine	26-33	mitogen-activated protein kinase 1	Homo sapiens	88-130
28901502-8	2017	Further study showed that harmine inhibited not only the basal phosphorylation level of extra-cellular signal-regulated kinase 1/2 (ERK1/2) and cyclic adenosine monophosphate response element-binding protein (CREB) but also EGF-induced ERK1/2 and CREB phosphorylation.	Harmine	26-33	mitogen-activated protein kinase 3	Homo sapiens	132-138
28901502-8	2017	Further study showed that harmine inhibited not only the basal phosphorylation level of extra-cellular signal-regulated kinase 1/2 (ERK1/2) and cyclic adenosine monophosphate response element-binding protein (CREB) but also EGF-induced ERK1/2 and CREB phosphorylation.	Harmine	26-33	cAMP responsive element binding protein 1	Homo sapiens	209-213
28901502-8	2017	Further study showed that harmine inhibited not only the basal phosphorylation level of extra-cellular signal-regulated kinase 1/2 (ERK1/2) and cyclic adenosine monophosphate response element-binding protein (CREB) but also EGF-induced ERK1/2 and CREB phosphorylation.	Harmine	26-33	epidermal growth factor	Homo sapiens	224-227
28901502-8	2017	Further study showed that harmine inhibited not only the basal phosphorylation level of extra-cellular signal-regulated kinase 1/2 (ERK1/2) and cyclic adenosine monophosphate response element-binding protein (CREB) but also EGF-induced ERK1/2 and CREB phosphorylation.	Harmine	26-33	mitogen-activated protein kinase 3	Homo sapiens	236-242
28901502-8	2017	Further study showed that harmine inhibited not only the basal phosphorylation level of extra-cellular signal-regulated kinase 1/2 (ERK1/2) and cyclic adenosine monophosphate response element-binding protein (CREB) but also EGF-induced ERK1/2 and CREB phosphorylation.	Harmine	26-33	cAMP responsive element binding protein 1	Homo sapiens	247-251
28901502-10	2017	In conclusion, our data revealed that harmine inhibited the proliferation and migration of SKOV-3 cells, which might be mediated by ERK/CREB pathway.	Harmine	38-45	mitogen-activated protein kinase 1	Homo sapiens	132-135
28901502-10	2017	In conclusion, our data revealed that harmine inhibited the proliferation and migration of SKOV-3 cells, which might be mediated by ERK/CREB pathway.	Harmine	38-45	cAMP responsive element binding protein 1	Homo sapiens	136-140
28625859-5	2017	Harmine treatment (20mg/kg) prevented the reductions in brain-derived neurotrophic factor (BDNF) protein levels and hippocampal neurogenesis induced by CUS.	Harmine	0-7	brain derived neurotrophic factor	Mus musculus	56-89
28625859-5	2017	Harmine treatment (20mg/kg) prevented the reductions in brain-derived neurotrophic factor (BDNF) protein levels and hippocampal neurogenesis induced by CUS.	Harmine	0-7	brain derived neurotrophic factor	Mus musculus	91-95
28625859-6	2017	In addition, harmine treatment (20mg/kg) increased the protein expression levels of glutamate transporter 1 (GLT-1) and prevented the CUS-induced decreases in glial fibrillary acidic protein (GFAP) protein expressions in the prefrontal cortex and hippocampus, suggesting that restoration of astrocytic functions may be a potential mechanism underlying the antidepressant-like effects of harmine.	Harmine	13-20	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	84-107
28625859-6	2017	In addition, harmine treatment (20mg/kg) increased the protein expression levels of glutamate transporter 1 (GLT-1) and prevented the CUS-induced decreases in glial fibrillary acidic protein (GFAP) protein expressions in the prefrontal cortex and hippocampus, suggesting that restoration of astrocytic functions may be a potential mechanism underlying the antidepressant-like effects of harmine.	Harmine	13-20	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	109-114
28625859-6	2017	In addition, harmine treatment (20mg/kg) increased the protein expression levels of glutamate transporter 1 (GLT-1) and prevented the CUS-induced decreases in glial fibrillary acidic protein (GFAP) protein expressions in the prefrontal cortex and hippocampus, suggesting that restoration of astrocytic functions may be a potential mechanism underlying the antidepressant-like effects of harmine.	Harmine	13-20	glial fibrillary acidic protein	Mus musculus	159-190
28625859-6	2017	In addition, harmine treatment (20mg/kg) increased the protein expression levels of glutamate transporter 1 (GLT-1) and prevented the CUS-induced decreases in glial fibrillary acidic protein (GFAP) protein expressions in the prefrontal cortex and hippocampus, suggesting that restoration of astrocytic functions may be a potential mechanism underlying the antidepressant-like effects of harmine.	Harmine	13-20	glial fibrillary acidic protein	Mus musculus	192-196
28735864-5	2017	Further, we showed that the Ser408 site on GLI1 was not phosphorylated in the presence of the selective DYRK1A inhibitor harmine.	Harmine	121-128	GLI family zinc finger 1	Homo sapiens	43-47
28551404-5	2017	As the most abundant compound, harmine inhibited tumor necrosis factor-alpha (TNF-alpha)- and lipopolysaccharides (LPS)-induced NF-kappaB transactivity and nuclear translocation in mouse macrophage RAW 264.7 cells.	Harmine	31-38	tumor necrosis factor	Mus musculus	78-87
28551404-7	2017	In an LPS-challenged mouse model, harmine markedly averted inflammatory damage of the lung, and decreased serum TNF-alpha, interleukin-1beta (IL-1beta) and IL-6 levels.	Harmine	34-41	tumor necrosis factor	Mus musculus	112-121
28551404-7	2017	In an LPS-challenged mouse model, harmine markedly averted inflammatory damage of the lung, and decreased serum TNF-alpha, interleukin-1beta (IL-1beta) and IL-6 levels.	Harmine	34-41	interleukin 1 beta	Mus musculus	123-140
28551404-7	2017	In an LPS-challenged mouse model, harmine markedly averted inflammatory damage of the lung, and decreased serum TNF-alpha, interleukin-1beta (IL-1beta) and IL-6 levels.	Harmine	34-41	interleukin 1 beta	Mus musculus	142-150
28551404-7	2017	In an LPS-challenged mouse model, harmine markedly averted inflammatory damage of the lung, and decreased serum TNF-alpha, interleukin-1beta (IL-1beta) and IL-6 levels.	Harmine	34-41	interleukin 6	Mus musculus	156-160
28264138-2	2017	Harmine, a natural product that selectively inhibits DYRK1A amongst kinases, could serve as a tool compound to better understand the biological processes that arise from DYRK1A inhibition.	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	53-59
28264138-2	2017	Harmine, a natural product that selectively inhibits DYRK1A amongst kinases, could serve as a tool compound to better understand the biological processes that arise from DYRK1A inhibition.	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	170-176
28264138-3	2017	On the other hand, harmine is also a potent inhibitor of monoamine oxidase A (MAO-A).	Harmine	19-26	monoamine oxidase A	Homo sapiens	57-76
28264138-3	2017	On the other hand, harmine is also a potent inhibitor of monoamine oxidase A (MAO-A).	Harmine	19-26	monoamine oxidase A	Homo sapiens	78-83
28322844-2	2017	While harmine is known to inhibit DYRK1A and intercalate into the DNA, tri-substitution was shown previously to modify its activity profile in favor of protein synthesis inhibition.	Harmine	6-13	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	34-40
28478808-12	2017	However, high concentration of harmine led to apoptosis characterized by the propidium/Annexin V-positive cell pollution, cell shrunk and the collapse of mitochondrial membrane potential.	Harmine	31-38	annexin A5	Homo sapiens	87-96
28250274-8	2017	Treatment with harmine, an inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), which is located in the DS critical region of chromosome 21, and gene knockdown of DYRK1A, upregulated neprilysin in fibroblasts.	Harmine	15-22	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	40-101
28250274-8	2017	Treatment with harmine, an inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), which is located in the DS critical region of chromosome 21, and gene knockdown of DYRK1A, upregulated neprilysin in fibroblasts.	Harmine	15-22	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	103-109
28270853-4	2017	The in vitro cytotoxicity of harmine evaluated by XTT assay indicated that harmine suppressed the proliferation of TPC-1 cells in a dose- and time-dependent manner.	Harmine	29-36	two pore channel 1	Mus musculus	115-120
28270853-4	2017	The in vitro cytotoxicity of harmine evaluated by XTT assay indicated that harmine suppressed the proliferation of TPC-1 cells in a dose- and time-dependent manner.	Harmine	75-82	two pore channel 1	Mus musculus	115-120
28270853-5	2017	Moreover, harmine dose-dependently induced apoptosis of TPC-1 cells through regulating the ratio of Bcl-2/Bax.	Harmine	10-17	two pore channel 1	Mus musculus	56-61
28270853-5	2017	Moreover, harmine dose-dependently induced apoptosis of TPC-1 cells through regulating the ratio of Bcl-2/Bax.	Harmine	10-17	B cell leukemia/lymphoma 2	Mus musculus	100-105
28270853-5	2017	Moreover, harmine dose-dependently induced apoptosis of TPC-1 cells through regulating the ratio of Bcl-2/Bax.	Harmine	10-17	BCL2-associated X protein	Mus musculus	106-109
28270853-6	2017	The colony forming ability of TPC-1 cells was also time-dependently inhibited by harmine.	Harmine	81-88	two pore channel 1	Mus musculus	30-35
28270853-7	2017	The inhibitory effects of harmine on migration and invasion of TPC-1 cells were studied by wound scratching and Transwell assays.	Harmine	26-33	two pore channel 1	Mus musculus	63-68
27918874-5	2017	Harmine administration was associated with neuroprotective effects such as reduced excitotoxicity, inflammation, and oxidative stress, and increased brain-derived neurotrophic factor (BDNF) levels.	Harmine	0-7	brain derived neurotrophic factor	Homo sapiens	149-182
27282658-4	2017	We identify the DYRK1A kinase inhibitor harmine, which phosphorylates Tau that is deregulated in Alzheimer"s disease, as a potentiator of cell death induced by non-toxic doses of doxorubicin.	Harmine	40-47	microtubule associated protein tau	Homo sapiens	70-73
27282658-5	2017	These observations suggest that harmine or other compounds that target the DYRK1A kinase my offer a new therapeutic opportunity to suppress doxorubicin age-related and dose-dependent cardiotoxicity.	Harmine	32-39	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	75-81
27918874-5	2017	Harmine administration was associated with neuroprotective effects such as reduced excitotoxicity, inflammation, and oxidative stress, and increased brain-derived neurotrophic factor (BDNF) levels.	Harmine	0-7	brain derived neurotrophic factor	Homo sapiens	184-188
26953159-6	2016	Induction of beta-cell proliferation by either 5-IT or harmine, another natural product DYRK1A inhibitor, was suppressed by coincubation with the calcineurin inhibitor FK506, suggesting involvement of DYRK1A and nuclear factor of activated T cells signaling.	Harmine	55-62	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	88-94
27957390-6	2016	Harmine has been reported as a potent inhibitor of the dual specificity tyrosine-phosphorylation-regulated kinase (DYRK1A), which regulates cell proliferation and brain development.	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	115-121
27957390-8	2016	INDY but not pargyline induced proliferation of hNPCs similarly to harmine, suggesting that inhibition of DYRK1A is a possible mechanism to explain harmine effects upon the proliferation of hNPCs.	Harmine	148-155	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	106-112
27957390-9	2016	Our findings show that harmine enhances proliferation of hNPCs and suggest that inhibition of DYRK1A may explain its effects upon proliferation in vitro and antidepressant effects in vivo.	Harmine	23-30	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	94-100
27805061-0	2016	Harmine Induces Adipocyte Thermogenesis through RAC1-MEK-ERK-CHD4 Axis.	Harmine	0-7	Rac family small GTPase 1	Mus musculus	48-52
27805061-0	2016	Harmine Induces Adipocyte Thermogenesis through RAC1-MEK-ERK-CHD4 Axis.	Harmine	0-7	midkine	Mus musculus	53-56
27805061-0	2016	Harmine Induces Adipocyte Thermogenesis through RAC1-MEK-ERK-CHD4 Axis.	Harmine	0-7	mitogen-activated protein kinase 1	Mus musculus	57-60
27805061-0	2016	Harmine Induces Adipocyte Thermogenesis through RAC1-MEK-ERK-CHD4 Axis.	Harmine	0-7	chromodomain helicase DNA binding protein 4	Mus musculus	61-65
27805061-5	2016	In vitro, harmine potently induced the expression of thermogenic genes in both brown and white adipocytes, which was largely abolished by inhibition of RAC1/MEK/ERK pathway.	Harmine	10-17	Rac family small GTPase 1	Mus musculus	152-156
27805061-5	2016	In vitro, harmine potently induced the expression of thermogenic genes in both brown and white adipocytes, which was largely abolished by inhibition of RAC1/MEK/ERK pathway.	Harmine	10-17	midkine	Mus musculus	157-160
27805061-5	2016	In vitro, harmine potently induced the expression of thermogenic genes in both brown and white adipocytes, which was largely abolished by inhibition of RAC1/MEK/ERK pathway.	Harmine	10-17	mitogen-activated protein kinase 1	Mus musculus	161-164
27805061-6	2016	Post-transcriptional modification analysis revealed that chromodomain helicase DNA binding protein 4 (CHD4) is a potential downstream target of harmine-mediated ERK activation.	Harmine	144-151	chromodomain helicase DNA binding protein 4	Mus musculus	57-100
27805061-6	2016	Post-transcriptional modification analysis revealed that chromodomain helicase DNA binding protein 4 (CHD4) is a potential downstream target of harmine-mediated ERK activation.	Harmine	144-151	chromodomain helicase DNA binding protein 4	Mus musculus	102-106
27805061-6	2016	Post-transcriptional modification analysis revealed that chromodomain helicase DNA binding protein 4 (CHD4) is a potential downstream target of harmine-mediated ERK activation.	Harmine	144-151	mitogen-activated protein kinase 1	Mus musculus	161-164
27805061-7	2016	CHD4 directly binds the proximal promoter region of Ucp1, which is displaced upon treatment of harmine, thereby serving as a negative modulator of Ucp1.	Harmine	95-102	chromodomain helicase DNA binding protein 4	Mus musculus	0-4
27805061-7	2016	CHD4 directly binds the proximal promoter region of Ucp1, which is displaced upon treatment of harmine, thereby serving as a negative modulator of Ucp1.	Harmine	95-102	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	52-56
27805061-7	2016	CHD4 directly binds the proximal promoter region of Ucp1, which is displaced upon treatment of harmine, thereby serving as a negative modulator of Ucp1.	Harmine	95-102	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	147-151
27280693-3	2016	Only a few potent and selective ABCG2 inhibitors have been discovered, i.e., fumitremorgin C (FTC), Ko143, and the alkaloid harmine, which contain a tetrahydro-beta-carboline or beta-carboline backbone, respectively.	Harmine	124-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	32-37
27624103-7	2016	Treatment with the control compound harmine, a Dyrk1a inhibitor, led to a significant increase in Ki-67+ beta-cells, whereas treatment with other compounds had limited to no effect on human beta-cell proliferation.	Harmine	36-43	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	47-53
27446381-0	2016	Harmine combined with paclitaxel inhibits tumor proliferation and induces apoptosis through down-regulation of cyclooxygenase-2 expression in gastric cancer.	Harmine	0-7	prostaglandin-endoperoxide synthase 2	Homo sapiens	111-127
26953159-6	2016	Induction of beta-cell proliferation by either 5-IT or harmine, another natural product DYRK1A inhibitor, was suppressed by coincubation with the calcineurin inhibitor FK506, suggesting involvement of DYRK1A and nuclear factor of activated T cells signaling.	Harmine	55-62	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	201-207
27004568-0	2016	Harmine induces cell cycle arrest and mitochondrial pathway-mediated cellular apoptosis in SW620 cells via inhibition of the Akt and ERK signaling pathways.	Harmine	0-7	AKT serine/threonine kinase 1	Homo sapiens	125-128
27004568-12	2016	In conclusion, harmine induces cell cycle arrest and mitochondrial pathway-mediated cellular apoptosis in SW620 cells via inhibition of the Akt and ERK signaling pathways.	Harmine	15-22	AKT serine/threonine kinase 1	Homo sapiens	140-143
26348003-12	2015	We demonstrated that harmine significantly reduced HSV-2-induced NF-kappaB activation, as well as IkappaB-alpha degradation and p65 nuclear translocation.	Harmine	21-28	nuclear factor kappa B subunit 1	Homo sapiens	65-74
26526348-0	2015	Effects of harmine, an acetylcholinesterase inhibitor, on spatial learning and memory of APP/PS1 transgenic mice and scopolamine-induced memory impairment mice.	Harmine	11-18	acetylcholinesterase	Mus musculus	23-43
26526348-1	2015	Harmine, a beta-carboline alkaloid present in Peganum harmala with a wide spectrum of pharmacological activities, has been shown to exert strong inhibition against acetylcholinesterase in vitro.	Harmine	0-7	acetylcholinesterase	Mus musculus	164-184
26526348-4	2015	In addition, whether harmine could penetrate blood brain barrier, interact with and inhibit acetylcholinesterase, and activate downstream signaling network was also investigated.	Harmine	21-28	acetylcholinesterase	Mus musculus	92-112
26526348-6	2015	Meanwhile, long-term consumption of harmine (20mg/kg) for 10 weeks also slightly benefited the impaired memory of APP/PS1 mice.	Harmine	36-43	presenilin 1	Mus musculus	118-121
26526348-8	2015	Molecular docking assay disclosed that harmine molecule could directly dock into the catalytic active site of acetylcholinesterase, which was partially confirmed by its in vivo inhibitory activity on acetylcholinesterase.	Harmine	39-46	acetylcholinesterase	Mus musculus	110-130
26526348-8	2015	Molecular docking assay disclosed that harmine molecule could directly dock into the catalytic active site of acetylcholinesterase, which was partially confirmed by its in vivo inhibitory activity on acetylcholinesterase.	Harmine	39-46	acetylcholinesterase	Mus musculus	200-220
26526348-9	2015	Taken together, all these results suggested that harmine could ameliorate impaired memory by enhancement of cholinergic neurotransmission via inhibiting the activity of acetylcholinesterase, which may contribute to its clinical use in the therapy of neurological diseases characterized with acetylcholinesterase deficiency.	Harmine	49-56	acetylcholinesterase	Mus musculus	169-189
26496827-4	2015	The beta-carboline alkaloid harmine has been demonstrated to exert neuroprotective actions in vivo, and the beneficial effects were specifically due to elevation of GLT-1.	Harmine	28-35	solute carrier family 1 member 2	Rattus norvegicus	165-170
26496827-10	2015	In addition, harmine significantly increased the protein expression of GLT-1, and markedly attenuated the expression levels of interleukin-1beta and tumor necrosis factor-alpha, thereby attenuating apoptotic neuronal death in the hippocampus.	Harmine	13-20	solute carrier family 1 member 2	Rattus norvegicus	71-76
26496827-10	2015	In addition, harmine significantly increased the protein expression of GLT-1, and markedly attenuated the expression levels of interleukin-1beta and tumor necrosis factor-alpha, thereby attenuating apoptotic neuronal death in the hippocampus.	Harmine	13-20	interleukin 1 beta	Rattus norvegicus	127-176
26067684-9	2015	Inversely, treatment of MI-induced HF rats with Dyrk1A inhibitor, either harmine or EGCG, improved the symptoms of HF, reversed the molecular changes of Dyrk1A and ASF, and regulated alternative splicing of CaMKIIdelta in HF rats.	Harmine	73-80	dual specificity tyrosine phosphorylation regulated kinase 1A	Rattus norvegicus	48-54
26067684-9	2015	Inversely, treatment of MI-induced HF rats with Dyrk1A inhibitor, either harmine or EGCG, improved the symptoms of HF, reversed the molecular changes of Dyrk1A and ASF, and regulated alternative splicing of CaMKIIdelta in HF rats.	Harmine	73-80	dual specificity tyrosine phosphorylation regulated kinase 1A	Rattus norvegicus	153-159
26622726-0	2015	Paclitaxel combined with harmine inhibits the migration and invasion of gastric cancer cells through downregulation of cyclooxygenase-2 expression.	Harmine	25-32	prostaglandin-endoperoxide synthase 2	Homo sapiens	119-135
25998054-5	2015	Importantly, both Treg cells generated using the DYRK1A inhibitor harmine and direct administration of harmine itself potently attenuate inflammation in multiple experimental models of systemic autoimmunity and mucosal inflammation.	Harmine	66-73	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	49-55
26192590-4	2015	Here we characterized a series of novel harmine analogs with minimal or absent MAO-A inhibitory activity.	Harmine	40-47	monoamine oxidase A	Homo sapiens	79-84
25068731-1	2015	In our study, a series of new harmine derivatives has been prepared by cycloaddition reaction using various arylnitrile oxides and evaluated in vitro against acetylcholinesterase and 5-lipoxygenase enzymes, MCF7 and HCT116 cancer cell lines.	Harmine	30-37	acetylcholinesterase (Cartwright blood group)	Homo sapiens	158-178
25068731-3	2015	The greatest activity against acetylcholinesterase (IC50 = 10.4 microM) was obtained for harmine 1 and cytotoxic activities (IC50 = 0.2 microM) for compound 3a.	Harmine	89-96	acetylcholinesterase (Cartwright blood group)	Homo sapiens	30-50
26382920-5	2015	Our further study found that Harmine, a natural compound, negatively regulates HR but not NHEJ by interfering Rad51 recruitment, resulting in severe cytotoxicity in hepatoma cells.	Harmine	29-36	RAD51 recombinase	Homo sapiens	110-115
25751815-0	2015	A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication.	Harmine	47-54	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	78-84
25617675-2	2015	Harmine nanosuspensions were transformed into harmine solid nanocrystals (HAR-SNC) via different stress of solidification process including freezing, lyophilization and spray-drying.	Harmine	0-7	lymphatic vessel endothelial hyaluronan receptor 1	Homo sapiens	74-77
25617675-2	2015	Harmine nanosuspensions were transformed into harmine solid nanocrystals (HAR-SNC) via different stress of solidification process including freezing, lyophilization and spray-drying.	Harmine	46-53	lymphatic vessel endothelial hyaluronan receptor 1	Homo sapiens	74-77
25238961-0	2014	Harmine mediated neuroprotection via evaluation of glutamate transporter 1 in a rat model of global cerebral ischemia.	Harmine	0-7	solute carrier family 1 member 2	Rattus norvegicus	51-74
25250831-1	2015	Harmine is a naturally occurring monoamine oxidase inhibitor that has recently been shown to selectively inhibit the dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A (DYRK1A).	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1A	Rattus norvegicus	117-182
25250831-1	2015	Harmine is a naturally occurring monoamine oxidase inhibitor that has recently been shown to selectively inhibit the dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A (DYRK1A).	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1A	Rattus norvegicus	184-190
25238961-4	2014	Preclinical findings implicate that Harmine present neuroprotection effects in a rat model of amyotrophic lateral sclerosis disease, and the beneficial effects were specifically due to up-regulation of GLT-1.	Harmine	36-43	solute carrier family 1 member 2	Rattus norvegicus	202-207
24176842-0	2014	Harmine induces apoptosis and inhibits tumor cell proliferation, migration and invasion through down-regulation of cyclooxygenase-2 expression in gastric cancer.	Harmine	0-7	prostaglandin-endoperoxide synthase 2	Homo sapiens	115-131
24154665-4	2014	MAO-A VT (an index of MAO-A density) was measured using [(11)C]harmine positron emission tomography (PET) in 42 subjects with MDEs secondary to major depressive disorder and 37 healthy controls.	Harmine	63-70	monoamine oxidase A	Homo sapiens	0-5
24154665-4	2014	MAO-A VT (an index of MAO-A density) was measured using [(11)C]harmine positron emission tomography (PET) in 42 subjects with MDEs secondary to major depressive disorder and 37 healthy controls.	Harmine	63-70	monoamine oxidase A	Homo sapiens	22-27
24898155-0	2014	Greater monoamine oxidase a binding in perimenopausal age as measured with carbon 11-labeled harmine positron emission tomography.	Harmine	93-100	monoamine oxidase A	Homo sapiens	8-27
24176842-9	2014	In addition, harmine significantly inhibited the expression of COX-2, PCNA, Bcl-2 and MMP-2 as well as increased Bax expression in gastric cancer cells.	Harmine	13-20	prostaglandin-endoperoxide synthase 2	Homo sapiens	63-68
24176842-9	2014	In addition, harmine significantly inhibited the expression of COX-2, PCNA, Bcl-2 and MMP-2 as well as increased Bax expression in gastric cancer cells.	Harmine	13-20	proliferating cell nuclear antigen	Homo sapiens	70-74
24176842-9	2014	In addition, harmine significantly inhibited the expression of COX-2, PCNA, Bcl-2 and MMP-2 as well as increased Bax expression in gastric cancer cells.	Harmine	13-20	BCL2 apoptosis regulator	Homo sapiens	76-81
24176842-9	2014	In addition, harmine significantly inhibited the expression of COX-2, PCNA, Bcl-2 and MMP-2 as well as increased Bax expression in gastric cancer cells.	Harmine	13-20	matrix metallopeptidase 2	Homo sapiens	86-91
24176842-9	2014	In addition, harmine significantly inhibited the expression of COX-2, PCNA, Bcl-2 and MMP-2 as well as increased Bax expression in gastric cancer cells.	Harmine	13-20	BCL2 associated X, apoptosis regulator	Homo sapiens	113-116
24176842-10	2014	These results collectively indicate that harmine induces apoptosis and inhibits proliferation, migration and invasion of human gastric cancer cells, which may be mediated by down-regulation of COX-2 expression.	Harmine	41-48	prostaglandin-endoperoxide synthase 2	Homo sapiens	193-198
25087965-2	2014	We previously reported that the harmala alkaloid, harmine, lengthens the circadian period of Bmal1 transcription in NIH 3T3 fibroblasts.	Harmine	50-57	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	93-98
25087965-4	2014	Harmine significantly lengthened the period of PER2::LUC expression in embryonic fibroblasts, in neuronal cells differentiated from neuronal progenitor cells and in SCN slices obtained from PER2::LUC mice.	Harmine	0-7	period circadian clock 2	Mus musculus	47-51
25087965-4	2014	Harmine significantly lengthened the period of PER2::LUC expression in embryonic fibroblasts, in neuronal cells differentiated from neuronal progenitor cells and in SCN slices obtained from PER2::LUC mice.	Harmine	0-7	period circadian clock 2	Mus musculus	190-194
25087965-5	2014	Although harmine did not induce the transient mRNA expression of clock genes such as Per1, Per2 and Bmal1 in embryonic fibroblasts, it significantly extended the half-life of PER2::LUC protein in neuronal cells and SCN slices.	Harmine	9-16	period circadian regulator 2	Homo sapiens	175-179
24109558-6	2013	Our data indicate that harmine exhibits a pronounced cytotoxicity and induces an anti-proliferation state in MCF-7 cells which is accompanied by a significant inhibition of telomerase activity and an induction of an accelerated senescence phenotype by over-expressing elements of the p53/p21 pathway.	Harmine	23-30	tumor protein p53	Homo sapiens	284-287
25287872-6	2013	Treatment with harmine reversed the increase in citrate synthase activity in the prefrontal cortex.	Harmine	15-22	citrate synthase	Rattus norvegicus	48-64
24109558-6	2013	Our data indicate that harmine exhibits a pronounced cytotoxicity and induces an anti-proliferation state in MCF-7 cells which is accompanied by a significant inhibition of telomerase activity and an induction of an accelerated senescence phenotype by over-expressing elements of the p53/p21 pathway.	Harmine	23-30	H3 histone pseudogene 16	Homo sapiens	288-291
23403377-1	2013	Positron emission tomography (PET) imaging of monoamine oxidases (MAO-A: [(11)C]harmine, [(11)C]clorgyline, and [(11)C]befloxatone; MAO-B: [(11)C]deprenyl-D2) has been actively pursued given clinical importance of MAOs in human neuropsychiatric disorders.	Harmine	80-87	monoamine oxidase A	Homo sapiens	66-71
23360763-3	2013	In the former case one of the new compounds, C624 (naphto [1,2-b]benzofuran-5,9-diol) displays a potency comparable to that of the first-in-class DYRK1A inhibitor, harmine, lacking however the drawback of drastically inhibiting monoamine oxidase-A (MAO-A) as harmine does.	Harmine	164-171	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	146-152
23509697-0	2013	Harmine and harmaline downregulate TCDD-induced Cyp1a1 in the livers and lungs of C57BL/6 mice.	Harmine	0-7	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	48-54
23116713-6	2013	Therefore, this study screened a compound library and identified the beta-carboline alkaloid harmine as a novel inducer of CCN2 in human chondrocytic HCS-2/8 cells and osteoarthritic articular chondrocytes.	Harmine	93-100	cellular communication network factor 2	Homo sapiens	123-127
23116713-9	2013	The chondroprotective effect of harmine was investigated under inflammatory condition by stimulation with TNFalpha, and harmine was shown to ameliorate TNFalpha-induced decrease in expression of CCN2 and cartilage markers.	Harmine	32-39	tumor necrosis factor	Homo sapiens	106-114
23116713-9	2013	The chondroprotective effect of harmine was investigated under inflammatory condition by stimulation with TNFalpha, and harmine was shown to ameliorate TNFalpha-induced decrease in expression of CCN2 and cartilage markers.	Harmine	32-39	tumor necrosis factor	Homo sapiens	152-160
23116713-9	2013	The chondroprotective effect of harmine was investigated under inflammatory condition by stimulation with TNFalpha, and harmine was shown to ameliorate TNFalpha-induced decrease in expression of CCN2 and cartilage markers.	Harmine	32-39	cellular communication network factor 2	Homo sapiens	195-199
23116713-9	2013	The chondroprotective effect of harmine was investigated under inflammatory condition by stimulation with TNFalpha, and harmine was shown to ameliorate TNFalpha-induced decrease in expression of CCN2 and cartilage markers.	Harmine	120-127	tumor necrosis factor	Homo sapiens	152-160
23116713-9	2013	The chondroprotective effect of harmine was investigated under inflammatory condition by stimulation with TNFalpha, and harmine was shown to ameliorate TNFalpha-induced decrease in expression of CCN2 and cartilage markers.	Harmine	120-127	cellular communication network factor 2	Homo sapiens	195-199
22923366-6	2013	This increase was abolished when CBS-deficient and Dyrk1A-transgenic mice were treated with harmine, an inhibitor of Dyrk1A kinase activity, which emphasizes the role of Dyrk1A activity on ERK and Akt activation.	Harmine	92-99	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	51-57
22923366-6	2013	This increase was abolished when CBS-deficient and Dyrk1A-transgenic mice were treated with harmine, an inhibitor of Dyrk1A kinase activity, which emphasizes the role of Dyrk1A activity on ERK and Akt activation.	Harmine	92-99	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	117-123
22923366-6	2013	This increase was abolished when CBS-deficient and Dyrk1A-transgenic mice were treated with harmine, an inhibitor of Dyrk1A kinase activity, which emphasizes the role of Dyrk1A activity on ERK and Akt activation.	Harmine	92-99	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	117-123
22923366-6	2013	This increase was abolished when CBS-deficient and Dyrk1A-transgenic mice were treated with harmine, an inhibitor of Dyrk1A kinase activity, which emphasizes the role of Dyrk1A activity on ERK and Akt activation.	Harmine	92-99	mitogen-activated protein kinase 1	Mus musculus	189-192
22923366-6	2013	This increase was abolished when CBS-deficient and Dyrk1A-transgenic mice were treated with harmine, an inhibitor of Dyrk1A kinase activity, which emphasizes the role of Dyrk1A activity on ERK and Akt activation.	Harmine	92-99	thymoma viral proto-oncogene 1	Mus musculus	197-200
23509697-1	2013	We previously demonstrated that Peganum harmala L. extract and its main active constituents, harmine and harmaline inhibit the 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated induction of the carcinogen-activating enzyme, Cyp1a1, in vitro.	Harmine	93-100	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	226-232
23509697-3	2013	Therefore, the aim of this study is to examine the effect of harmine and harmaline on TCDD-mediated induction of Cyp1a1 in mice livers and lungs.	Harmine	61-68	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	113-119
23509697-9	2013	The effect of harmine and harmaline on TCDD-mediated induction of Cyp1a1 mRNA, protein, and activity levels was determined using real-time PCR, Western blot analysis, and 7-ethoxyresurofin as a substrate, respectively.	Harmine	14-21	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	66-72
23509697-10	2013	Our results showed that harmine and harmaline significantly decreased the TCDD-mediated induction of Cyp1a1 in both the livers and lungs.	Harmine	24-31	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	101-107
23509697-11	2013	We concluded that harmine and harmaline are promising candidate to inhibit TCDD-mediated induction of Cyp1a1 in mice hepatic and extrahepatic tissues.	Harmine	18-25	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	102-108
23076833-2	2013	Harmine is an inhibitor of monoamine oxidase A (MAO-A) and interacts in vitro with several pharmacological targets which modulate dopamine (DA) neurotransmission.	Harmine	0-7	monoamine oxidase A	Rattus norvegicus	27-46
23076833-2	2013	Harmine is an inhibitor of monoamine oxidase A (MAO-A) and interacts in vitro with several pharmacological targets which modulate dopamine (DA) neurotransmission.	Harmine	0-7	monoamine oxidase A	Rattus norvegicus	48-53
22186668-2	2012	We measured the effect of changes in MAO-A substrate on MAO-A binding in regions implicated in affective and neurodegenerative disease with [(11)C]-harmine positron emission tomography in healthy volunteers.	Harmine	146-155	monoamine oxidase A	Homo sapiens	56-61
22770529-2	2012	Harmine is known for its anticancer properties and is a DYRK1A inhibitor.	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	56-62
22335895-3	2012	Based on information obtained from a structure-activity relationship study previously conducted for an acridine series of haspin inhibitors in conjunction with in silico docking using a recently disclosed crystal structure of the kinase, harmine analogs were designed that resulted in significantly increased haspin kinase inhibitory potency.	Harmine	238-245	histone H3 associated protein kinase	Mus musculus	122-128
22335895-3	2012	Based on information obtained from a structure-activity relationship study previously conducted for an acridine series of haspin inhibitors in conjunction with in silico docking using a recently disclosed crystal structure of the kinase, harmine analogs were designed that resulted in significantly increased haspin kinase inhibitory potency.	Harmine	238-245	histone H3 associated protein kinase	Mus musculus	309-315
22335895-4	2012	The harmine derivatives also demonstrated less activity towards DYRK2 compared to the acridine series.	Harmine	4-11	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2	Mus musculus	64-69
22877698-4	2012	However, when applied over the same concentration range, harmine significantly inhibited C-shapes elicited by cocaine, with a concentration of 0.1 muM producing almost 90% inhibition.	Harmine	57-64	latexin	Homo sapiens	147-150
22877698-6	2012	When tested in the presence of the glutamate transporter inhibitor dihydrokainate (DHK) (0.1, 1 muM), harmine (0.1 muM) efficacy against cocaine-induced C-shapes was significantly reduced.	Harmine	102-109	latexin	Homo sapiens	96-99
22877698-6	2012	When tested in the presence of the glutamate transporter inhibitor dihydrokainate (DHK) (0.1, 1 muM), harmine (0.1 muM) efficacy against cocaine-induced C-shapes was significantly reduced.	Harmine	102-109	latexin	Homo sapiens	115-118
22335895-2	2012	High throughput screening of approximately 140,000 compounds identified the beta-carbolines harmine and harmol as moderately potent haspin kinase inhibitors.	Harmine	92-99	histone H3 associated protein kinase	Mus musculus	132-138
22001777-0	2012	Transcriptional and posttranslational inhibition of dioxin-mediated induction of CYP1A1 by harmine and harmol.	Harmine	91-98	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	81-87
21401525-6	2012	Furthermore, EMSA (electrophoretic mobility-shift assay) and Western-blot analysis showed that harmine enhanced the transactivating function of RORalpha (retinoid-related orphan receptor alpha), probably by increasing its nuclear translocation.	Harmine	95-102	RAR related orphan receptor A	Homo sapiens	144-152
21401525-6	2012	Furthermore, EMSA (electrophoretic mobility-shift assay) and Western-blot analysis showed that harmine enhanced the transactivating function of RORalpha (retinoid-related orphan receptor alpha), probably by increasing its nuclear translocation.	Harmine	95-102	RAR related orphan receptor A	Homo sapiens	154-192
21401525-7	2012	Exogenous expression of RORalpha also caused a long period, confirming the phenotype indicated by harmine.	Harmine	98-105	RAR related orphan receptor A	Homo sapiens	24-32
21401525-8	2012	These results suggest that harmine extends the circadian period by enhancing RORalpha function and that harmine is a new candidate that contributes to the control of period length in mammalian cells.	Harmine	27-34	RAR related orphan receptor A	Homo sapiens	77-85
22001777-2	2012	We previously demonstrated that harmine inhibits the dioxin-mediated induction of Cyp1a1 activity in murine hepatoma cells.	Harmine	32-39	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	82-88
22001777-3	2012	Therefore, the aim of this study is to determine the effect of harmine and its main metabolite, harmol, on the dioxin-mediated induction of CYP1A1 in human HepG2 and murine Hepa 1c1c7 hepatoma cells.	Harmine	63-70	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	140-146
22001777-4	2012	Our results showed that harmine and harmol significantly inhibited the dioxin-mediated induction of CYP1A1 at mRNA, protein, and activity levels in a concentration-dependent manner in human and murine hepatoma cells.	Harmine	24-31	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	100-106
22001777-5	2012	Moreover, harmine and harmol inhibited the AhR-dependent luciferase activity and the activation and transformation of AhR using the electrophoretic mobility shift assay.	Harmine	10-17	aryl hydrocarbon receptor	Homo sapiens	43-46
22001777-5	2012	Moreover, harmine and harmol inhibited the AhR-dependent luciferase activity and the activation and transformation of AhR using the electrophoretic mobility shift assay.	Harmine	10-17	aryl hydrocarbon receptor	Homo sapiens	118-121
21570953-9	2011	The bone morphogenetic protein (BMP) antagonist noggin and its receptor kinase inhibitors dorsomorphin and LDN-193189 attenuated harmine-promoted ALP activity.	Harmine	129-136	noggin	Mus musculus	48-54
23300602-6	2012	Harmine also prevented p53 degradation in the presence of cycloheximide and activated nuclear accumulation of p53 followed by increasing its transcriptional activity in endothelial cells.	Harmine	0-7	transformation related protein 53, pseudogene	Mus musculus	23-26
23300602-6	2012	Harmine also prevented p53 degradation in the presence of cycloheximide and activated nuclear accumulation of p53 followed by increasing its transcriptional activity in endothelial cells.	Harmine	0-7	transformation related protein 53, pseudogene	Mus musculus	110-113
23300602-9	2012	Our results suggested a novel mechanism and bioactivity of harmine, which inhibited tumor growth by activating the p53 signaling pathway and blocking angiogenesis in endothelial cells.	Harmine	59-66	transformation related protein 53, pseudogene	Mus musculus	115-118
22558087-0	2012	JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21.	Harmine	37-44	tumor protein p53	Homo sapiens	111-114
22558087-0	2012	JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21.	Harmine	37-44	H3 histone pseudogene 16	Homo sapiens	144-147
21463543-0	2011	Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John"s wort: an [11C]-harmine PET study.	Harmine	132-139	monoamine oxidase A	Homo sapiens	0-19
23300602-0	2012	A natural small molecule harmine inhibits angiogenesis and suppresses tumour growth through activation of p53 in endothelial cells.	Harmine	25-32	transformation related protein 53, pseudogene	Mus musculus	106-109
23300602-4	2012	Here, we identified harmine (beta-carboline alkaloid) as a novel activator of p53 signaling involved in inhibition of angiogenesis and tumor growth.	Harmine	20-27	transformation related protein 53, pseudogene	Mus musculus	78-81
23300602-5	2012	Harmine induced p53 phosphorylation and disrupted the p53-MDM2 interaction.	Harmine	0-7	transformation related protein 53, pseudogene	Mus musculus	16-19
23300602-5	2012	Harmine induced p53 phosphorylation and disrupted the p53-MDM2 interaction.	Harmine	0-7	transformation related protein 53, pseudogene	Mus musculus	54-57
23300602-5	2012	Harmine induced p53 phosphorylation and disrupted the p53-MDM2 interaction.	Harmine	0-7	transformed mouse 3T3 cell double minute 2	Mus musculus	58-62
21433154-4	2011	Harmine, harmol and harmane exhibited noncompetitive inhibition on the activity of CYP3A4 with K(i) values of 16.76, 5.13 and 1.66 muM, respectively.	Harmine	0-7	latexin	Homo sapiens	131-134
21433154-6	2011	Harmaline, harmine and harmol showed typical competitive inhibition on the activity of CYP2D6 with K(i) values of 20.69, 36.48 and 47.11 muM, respectively.	Harmine	11-18	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	87-93
21433154-6	2011	Harmaline, harmine and harmol showed typical competitive inhibition on the activity of CYP2D6 with K(i) values of 20.69, 36.48 and 47.11 muM, respectively.	Harmine	11-18	latexin	Homo sapiens	137-140
21504804-3	2011	Orphan ligand library screening using this system identified the beta-carboline derivative harmine, which is a highly potent inhibitor of dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A), to be an NFAT regulator in osteoclasts.	Harmine	91-98	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	138-199
21504804-3	2011	Orphan ligand library screening using this system identified the beta-carboline derivative harmine, which is a highly potent inhibitor of dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A), to be an NFAT regulator in osteoclasts.	Harmine	91-98	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	201-207
21504804-4	2011	RAW264.7 cells highly expressed DYRK1A protein, and in vitro phosphorylation assay demonstrated that harmine directly inhibited the DYRK1A-mediated phosphorylation (in-activation) of NFATc1.	Harmine	101-108	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	32-38
21504804-4	2011	RAW264.7 cells highly expressed DYRK1A protein, and in vitro phosphorylation assay demonstrated that harmine directly inhibited the DYRK1A-mediated phosphorylation (in-activation) of NFATc1.	Harmine	101-108	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	132-138
21504804-4	2011	RAW264.7 cells highly expressed DYRK1A protein, and in vitro phosphorylation assay demonstrated that harmine directly inhibited the DYRK1A-mediated phosphorylation (in-activation) of NFATc1.	Harmine	101-108	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	183-189
21504804-5	2011	Harmine promoted the dephosphorylation (activation) of NFATc1 in RAW264.7 cells within 24h, and it significantly increased the expression of NFATc1 in RAW264.7 cells and mouse primary bone marrow macrophages (BMMs) both in the presence and absence of RANKL stimulation.	Harmine	0-7	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	55-61
21504804-5	2011	Harmine promoted the dephosphorylation (activation) of NFATc1 in RAW264.7 cells within 24h, and it significantly increased the expression of NFATc1 in RAW264.7 cells and mouse primary bone marrow macrophages (BMMs) both in the presence and absence of RANKL stimulation.	Harmine	0-7	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	141-147
21504804-5	2011	Harmine promoted the dephosphorylation (activation) of NFATc1 in RAW264.7 cells within 24h, and it significantly increased the expression of NFATc1 in RAW264.7 cells and mouse primary bone marrow macrophages (BMMs) both in the presence and absence of RANKL stimulation.	Harmine	0-7	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	251-256
21504804-6	2011	Although harmine promoted NFATc1 expression and stimulated target genes for osteoclastogenesis, cell-cell fusion and the formation of TRAP-positive multinucleated osteoclasts from RAW264.7 cells and BMMs was significantly inhibited by harmine treatment.	Harmine	9-16	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	26-32
21504804-7	2011	Meanwhile, harmine remarkably promoted the expression of inhibitor of DNA binding/differentiation-2 (Id2), which is a negative regulator for osteoclastogenesis, in RAW264.7 cells and BMMs.	Harmine	11-18	inhibitor of DNA binding 2	Mus musculus	101-104
21504804-8	2011	An Id2-null-mutant showed slightly increased osteoclast formation from BMMs, and the harmine-mediated inhibition of osteoclast formation was abolished in the BMMs of Id2-null-mutant mice.	Harmine	85-92	inhibitor of DNA binding 2	Mus musculus	3-6
21504804-8	2011	An Id2-null-mutant showed slightly increased osteoclast formation from BMMs, and the harmine-mediated inhibition of osteoclast formation was abolished in the BMMs of Id2-null-mutant mice.	Harmine	85-92	inhibitor of DNA binding 2	Mus musculus	166-169
21504804-9	2011	These results suggest that harmine is a potent activator of NFATc1 that interferes with the function of DYRK1A in osteoclast precursors and also up-regulates Id2 protein, which may dominantly inhibit expression pathways associated with cell-cell fusion, thereby leading to the disruption of the fusion events mediating osteoclastogenesis.	Harmine	27-34	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	60-66
21504804-9	2011	These results suggest that harmine is a potent activator of NFATc1 that interferes with the function of DYRK1A in osteoclast precursors and also up-regulates Id2 protein, which may dominantly inhibit expression pathways associated with cell-cell fusion, thereby leading to the disruption of the fusion events mediating osteoclastogenesis.	Harmine	27-34	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	104-110
21504804-9	2011	These results suggest that harmine is a potent activator of NFATc1 that interferes with the function of DYRK1A in osteoclast precursors and also up-regulates Id2 protein, which may dominantly inhibit expression pathways associated with cell-cell fusion, thereby leading to the disruption of the fusion events mediating osteoclastogenesis.	Harmine	27-34	inhibitor of DNA binding 2	Mus musculus	158-161
21504804-10	2011	The small molecule harmine is therefore expected to provide an experimental tool for investigating signaling cascades in osteoclastogenesis, especially those centered on DYRK1A-mediated NFATc1 and Id2 regulation.	Harmine	19-26	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	170-176
21504804-10	2011	The small molecule harmine is therefore expected to provide an experimental tool for investigating signaling cascades in osteoclastogenesis, especially those centered on DYRK1A-mediated NFATc1 and Id2 regulation.	Harmine	19-26	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	186-192
21504804-10	2011	The small molecule harmine is therefore expected to provide an experimental tool for investigating signaling cascades in osteoclastogenesis, especially those centered on DYRK1A-mediated NFATc1 and Id2 regulation.	Harmine	19-26	inhibitor of DNA binding 2	Mus musculus	197-200
21570953-12	2011	Furthermore, BMP-responsive and Runx2-responsive reporters were activated by harmine treatment.	Harmine	77-84	runt related transcription factor 2	Mus musculus	32-37
21570953-13	2011	Taken together, these results indicate that harmine enhances osteoblast differentiation probably by inducing the expressions of BMPs and activating BMP and Runx2 pathways.	Harmine	44-51	runt related transcription factor 2	Mus musculus	156-161
20810002-7	2011	MAOA binding was measured with [11C]harmine positron emission tomography (PET) in prefrontal brain regions and personality traits were measured with the NEO Personality Inventory Revised (NEO PI-R).	Harmine	36-43	monoamine oxidase A	Homo sapiens	0-4
21034752-9	2011	We next tested its efficacy in both wild type animals and in an ALS animal model of disease and demonstrated that harmine effectively increased GLT-1 protein and glutamate transporter activity in vivo.	Harmine	114-121	solute carrier family 1 member 2	Homo sapiens	144-149
21838142-3	2011	Results show harmine in form of base and salt in water and in mixture of DMSO and water has the hightest inhibition activity on ACHE using eserine as reference substance.	Harmine	13-20	acetylcholinesterase (Cartwright blood group)	Homo sapiens	128-132
21838142-4	2011	Harmalol in form of salt in water and harmine in form of base and salt in mixture of DMSO and water has the hightest activity on BUCHE.	Harmine	38-45	butyrylcholinesterase	Homo sapiens	129-134
21034752-7	2011	When screening a library of 1040 FDA approved compounds and natural products, we identified harmine, a naturally occurring beta-carboline alkaloid, as one of the top hits for activating the EAAT2 promoter.	Harmine	92-99	solute carrier family 1 member 2	Homo sapiens	190-195
21034752-8	2011	We further tested harmine in our in vitro cell culture systems and confirmed its ability to increase EAAT2/GLT1 gene expression and functional glutamate uptake activity.	Harmine	18-25	solute carrier family 1 member 2	Homo sapiens	101-106
21034752-8	2011	We further tested harmine in our in vitro cell culture systems and confirmed its ability to increase EAAT2/GLT1 gene expression and functional glutamate uptake activity.	Harmine	18-25	solute carrier family 1 member 2	Homo sapiens	107-111
21573099-0	2011	beta-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer"s disease-related sites.	Harmine	36-43	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	53-59
21573099-0	2011	beta-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer"s disease-related sites.	Harmine	36-43	microtubule associated protein tau	Homo sapiens	64-67
21573099-1	2011	Harmine, a beta-carboline alkaloid, is a high affinity inhibitor of the dual specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) protein.	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	72-133
21573099-1	2011	Harmine, a beta-carboline alkaloid, is a high affinity inhibitor of the dual specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) protein.	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	135-141
21573099-5	2011	Here we test the ability of harmine, and numerous additional beta-carboline compounds, to inhibit the DYRK1A dependent phosphorylation of tau protein on serine 396, serine 262/serine 356 (12E8 epitope), and threonine 231 in cell culture assays and in vitro phosphorylation assays.	Harmine	28-35	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	102-108
21573099-5	2011	Here we test the ability of harmine, and numerous additional beta-carboline compounds, to inhibit the DYRK1A dependent phosphorylation of tau protein on serine 396, serine 262/serine 356 (12E8 epitope), and threonine 231 in cell culture assays and in vitro phosphorylation assays.	Harmine	28-35	microtubule associated protein tau	Homo sapiens	138-141
21183355-1	2011	Previous studies have shown that harmine is a reversible inhibitor of human monoamine oxidase A (MAO-A).	Harmine	33-40	monoamine oxidase A	Homo sapiens	76-95
21429205-8	2011	Furthermore, RT-PCR analysis showed that harmine induced apoptosis in B16F-10 melanoma cells by up-regulating Bax and activating Caspase-3, 9 and p53 and down-regulating Bcl-2.	Harmine	41-48	BCL2-associated X protein	Mus musculus	110-113
21429205-8	2011	Furthermore, RT-PCR analysis showed that harmine induced apoptosis in B16F-10 melanoma cells by up-regulating Bax and activating Caspase-3, 9 and p53 and down-regulating Bcl-2.	Harmine	41-48	caspase 3	Mus musculus	129-138
21429205-8	2011	Furthermore, RT-PCR analysis showed that harmine induced apoptosis in B16F-10 melanoma cells by up-regulating Bax and activating Caspase-3, 9 and p53 and down-regulating Bcl-2.	Harmine	41-48	transformation related protein 53, pseudogene	Mus musculus	146-149
21429205-8	2011	Furthermore, RT-PCR analysis showed that harmine induced apoptosis in B16F-10 melanoma cells by up-regulating Bax and activating Caspase-3, 9 and p53 and down-regulating Bcl-2.	Harmine	41-48	B cell leukemia/lymphoma 2	Mus musculus	170-175
21429205-9	2011	Harmine also up-regulated Caspase-8 and Bid, indicating that harmine affected both extrinsic and intrinsic pathways of apoptosis.	Harmine	0-7	caspase 8	Mus musculus	26-35
21429205-9	2011	Harmine also up-regulated Caspase-8 and Bid, indicating that harmine affected both extrinsic and intrinsic pathways of apoptosis.	Harmine	0-7	BH3 interacting domain death agonist	Mus musculus	40-43
21429205-9	2011	Harmine also up-regulated Caspase-8 and Bid, indicating that harmine affected both extrinsic and intrinsic pathways of apoptosis.	Harmine	61-68	caspase 8	Mus musculus	26-35
21185805-0	2011	Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	44-105
21185805-0	2011	Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	107-113
21185805-3	2011	In this study, we show that harmine functions as an ATP-competitive inhibitor against Dyrk1A.	Harmine	28-35	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	86-92
21185805-4	2011	Our conclusion is supported by kinetic analysis of harmine inhibition as well as by the characterization of a Dyrk1A mutation conferring significant resistance to harmine.	Harmine	163-170	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	110-116
21185805-6	2011	The V306A mutation offers harmine resistance by differentially altering Dyrk1A affinity for harmine and ATP.	Harmine	26-33	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	72-78
21185805-6	2011	The V306A mutation offers harmine resistance by differentially altering Dyrk1A affinity for harmine and ATP.	Harmine	92-99	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	72-78
21185805-9	2011	Our results reveal that harmine inhibits Dyrk1A activity by interacting with residues in the ATP-binding pocket and displacing ATP.	Harmine	24-31	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	41-47
21185805-10	2011	Our results also suggest that harmine will be a good lead compound for further designing of selective ATP-competitive Dyrk1A inhibitors through exploration of the ATP-binding pocket of Dyrk1A.	Harmine	30-37	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	118-124
21185805-10	2011	Our results also suggest that harmine will be a good lead compound for further designing of selective ATP-competitive Dyrk1A inhibitors through exploration of the ATP-binding pocket of Dyrk1A.	Harmine	30-37	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	185-191
21047508-4	2011	We found that harmine, a beta-carboline alkaloid, inhibited multinucleated osteoclast formation induced by receptor activator of nuclear factor-kappaB ligand (RANKL) in RAW264.7 cells.	Harmine	14-21	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	107-157
21047508-4	2011	We found that harmine, a beta-carboline alkaloid, inhibited multinucleated osteoclast formation induced by receptor activator of nuclear factor-kappaB ligand (RANKL) in RAW264.7 cells.	Harmine	14-21	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	159-164
21047508-6	2011	Furthermore, harmine prevented RANKL-induced bone resorption in both cell and bone tissue cultures.	Harmine	13-20	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	31-36
21047508-9	2011	In mechanistic studies, we found that harmine inhibited the RANKL-induced expression of c-Fos and subsequent expression of nuclear factor of activated T cells (NFAT) c1, which is a master regulator of osteoclastogenesis.	Harmine	38-45	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	60-65
21047508-9	2011	In mechanistic studies, we found that harmine inhibited the RANKL-induced expression of c-Fos and subsequent expression of nuclear factor of activated T cells (NFAT) c1, which is a master regulator of osteoclastogenesis.	Harmine	38-45	FBJ osteosarcoma oncogene	Mus musculus	88-93
21047508-11	2011	These results indicate that harmine inhibits osteoclast formation via downregulation of c-Fos and NFATc1 induced by RANKL and represses bone resorption.	Harmine	28-35	FBJ osteosarcoma oncogene	Mus musculus	88-93
21047508-11	2011	These results indicate that harmine inhibits osteoclast formation via downregulation of c-Fos and NFATc1 induced by RANKL and represses bone resorption.	Harmine	28-35	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	98-104
21047508-11	2011	These results indicate that harmine inhibits osteoclast formation via downregulation of c-Fos and NFATc1 induced by RANKL and represses bone resorption.	Harmine	28-35	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	116-121
21183355-1	2011	Previous studies have shown that harmine is a reversible inhibitor of human monoamine oxidase A (MAO-A).	Harmine	33-40	monoamine oxidase A	Homo sapiens	97-102
21183355-2	2011	Moreover, the crystal structure of human MAO-A in complex with harmine has been recently solved.	Harmine	63-70	monoamine oxidase A	Homo sapiens	41-46
21183355-3	2011	This crystal structure shows that close to the methoxy group of the harmine moiety, a lipophilic pocket is left vacant within the binding site of human MAO-A.	Harmine	68-75	monoamine oxidase A	Homo sapiens	152-157
21183355-7	2011	The results show that O-alkylated compounds with lipophilic groups like cyclohexyl, phenyl and aliphatic chains increase the inhibition of MAO-A compared to harmine.	Harmine	157-164	monoamine oxidase A	Homo sapiens	139-144
21183355-11	2011	However, several compounds show a better inhibition on MAO-B compared to harmine.	Harmine	73-80	monoamine oxidase B	Homo sapiens	55-60
20219660-14	2010	Among various constituents of Banisteriopsis caapi, harmine (7), harmaline (6) and tetrahydroharmine (5) are responsible for MAO-A inhibition, while two major proanthocyanidines, epicatechin (8) and procyanidine B2 (9) produce antioxidant effects.	Harmine	52-59	monoamine oxidase A	Homo sapiens	125-130
20686906-0	2010	Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in rat hippocampus.	Harmine	26-33	brain-derived neurotrophic factor	Rattus norvegicus	84-88
20686906-7	2010	Brain-derived neurotrophic factor (BDNF) hippocampal levels were assessed in imipramine and harmine-treated rats by ELISA sandwich assay.	Harmine	92-99	brain-derived neurotrophic factor	Rattus norvegicus	0-33
20686906-8	2010	Interestingly, chronic administration of harmine at the higher doses (10 and 15 mg/kg), but not imipramine, increased BDNF protein levels in rat hippocampus.	Harmine	41-48	brain-derived neurotrophic factor	Rattus norvegicus	118-122
21372424-3	2011	A harmala alkaloid, harmine, an opium alkaloid, papaverine, and Lycoris alkaloids, lycorine and lycoricidinol, showed TNF-alpha suppressive activities stronger than or comparable to that of a reference polyphenol, butein, in RAW264 cells (IC(50)=4, 10, 2.1, 0.02, and 8 microM, respectively).	Harmine	20-27	tumor necrosis factor	Mus musculus	118-127
21372424-6	2011	In addition, harmine was found to suppress interleukin-6 (IL-6) production in RAW264 cells.	Harmine	13-20	interleukin 6	Mus musculus	43-56
21372424-6	2011	In addition, harmine was found to suppress interleukin-6 (IL-6) production in RAW264 cells.	Harmine	13-20	interleukin 6	Mus musculus	58-62
21372424-10	2011	In conclusion, some herbal alkaloids like harmine, in spite of lacking antioxidative property, have potential as anti-inflammatory agents that strongly suppress TNF-alpha and NO production by a unique mechanism.	Harmine	42-49	tumor necrosis factor	Mus musculus	161-170
21967457-5	2011	Higher expression levels of pro-metastatic genes such as matrix metalloproteinase-9 (MMP-9), extracellular signal[en]regulated kinase (ERK), and vascular endothelial factors (VEGFs), all of which play important roles in cancer cell migration and invasion, were observed in the metastatic group compared with normal, but were all down-regulated by treatment with harmine.	Harmine	362-369	matrix metallopeptidase 9	Mus musculus	57-83
21967457-7	2011	In conclusion, harmine exerts anti-metastatic activity and this effect could be linked to the metastasis-related signaling pathway that includes ERK, VEGF, and MMPs.	Harmine	15-22	vascular endothelial growth factor A	Mus musculus	150-154
21967457-7	2011	In conclusion, harmine exerts anti-metastatic activity and this effect could be linked to the metastasis-related signaling pathway that includes ERK, VEGF, and MMPs.	Harmine	15-22	matrix metallopeptidase 9	Mus musculus	160-164
20858484-0	2010	Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro.	Harmine	0-7	vascular endothelial growth factor A	Mus musculus	68-72
20858484-0	2010	Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro.	Harmine	0-7	tissue inhibitor of metalloproteinase 1	Mus musculus	79-83
20858484-5	2010	A drastic elevation in serum pro-angiogenic factors such as vascular endothelial growth factor (VEGF), nitric oxide (NO) and pro-inflammatory cytokines in angiogenesis induced animals was significantly decreased by harmine treatment.	Harmine	215-222	vascular endothelial growth factor A	Mus musculus	60-94
20858484-5	2010	A drastic elevation in serum pro-angiogenic factors such as vascular endothelial growth factor (VEGF), nitric oxide (NO) and pro-inflammatory cytokines in angiogenesis induced animals was significantly decreased by harmine treatment.	Harmine	215-222	vascular endothelial growth factor A	Mus musculus	96-100
20858484-6	2010	At the same time harmine increased anti-tumour factors like interleukin-2 (IL-2) and tissue inhibitor metalloprotease (TIMP).	Harmine	17-24	interleukin 2	Mus musculus	60-73
20858484-6	2010	At the same time harmine increased anti-tumour factors like interleukin-2 (IL-2) and tissue inhibitor metalloprotease (TIMP).	Harmine	17-24	interleukin 2	Mus musculus	75-79
20858484-6	2010	At the same time harmine increased anti-tumour factors like interleukin-2 (IL-2) and tissue inhibitor metalloprotease (TIMP).	Harmine	17-24	tissue inhibitor of metalloproteinase 1	Mus musculus	85-117
20858484-6	2010	At the same time harmine increased anti-tumour factors like interleukin-2 (IL-2) and tissue inhibitor metalloprotease (TIMP).	Harmine	17-24	tissue inhibitor of metalloproteinase 1	Mus musculus	119-123
20858484-7	2010	Moreover nuclear factor (NF)-kappaB and other transcription factors like CREB, ATF-2 involved in tumour development and angiogenesis were also inhibited by harmine.	Harmine	156-163	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	9-35
20858484-7	2010	Moreover nuclear factor (NF)-kappaB and other transcription factors like CREB, ATF-2 involved in tumour development and angiogenesis were also inhibited by harmine.	Harmine	156-163	cAMP responsive element binding protein 1	Mus musculus	73-77
20858484-7	2010	Moreover nuclear factor (NF)-kappaB and other transcription factors like CREB, ATF-2 involved in tumour development and angiogenesis were also inhibited by harmine.	Harmine	156-163	activating transcription factor 2	Mus musculus	79-84
20858484-11	2010	Production of other factors by tumour cells which are involved in angiogenesis like cyclooxygenase (COX-2), inducible nitric oxide synthase (iNOS) and matrix metalloproteases (MMPs) were also decrease by the treatment with harmine.	Harmine	223-230	cytochrome c oxidase II, mitochondrial	Mus musculus	100-105
20858484-11	2010	Production of other factors by tumour cells which are involved in angiogenesis like cyclooxygenase (COX-2), inducible nitric oxide synthase (iNOS) and matrix metalloproteases (MMPs) were also decrease by the treatment with harmine.	Harmine	223-230	nitric oxide synthase 2, inducible	Mus musculus	108-139
21150338-5	2010	The SOD and CAT activities increased with acute and chronic treatments with imipramine and harmine, compared to control group in prefrontal cortex and hippocampus.	Harmine	91-98	catalase	Rattus norvegicus	12-15
19796173-0	2009	Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.	Harmine	0-7	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	45-51
19772900-6	2010	Interestingly, treatment with harmine reversed anhedonia, the increase of adrenal gland weight, normalized ACTH circulating levels and BDNF protein levels.	Harmine	30-37	brain-derived neurotrophic factor	Rattus norvegicus	135-139
20036304-8	2010	Inhibition of MAO-A by seed extracts was quantitatively attributed to harmaline and harmine whereas inhibition by root extracts came from harmine with no additional interferences.	Harmine	84-91	monoamine oxidase A	Homo sapiens	14-19
19548284-6	2010	Harmine reduced resistance to the anticancer drugs mitoxantrone and camptothecin mediated by BCRP and might be an interesting new reversal agent.	Harmine	0-7	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	93-97
19632287-0	2009	Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus.	Harmine	6-13	brain-derived neurotrophic factor	Rattus norvegicus	79-83
19632287-3	2009	The present study aims to compare the behavioral effects and the BDNF hippocampus levels of acute administration of harmine and imipramine in rats.	Harmine	116-123	brain-derived neurotrophic factor	Rattus norvegicus	65-69
19632287-5	2009	Afterwards, hippocampal BDNF protein levels were assessed in imipramine- and harmine-treated rats by ELISA-sandwich assay.	Harmine	77-84	brain-derived neurotrophic factor	Rattus norvegicus	24-28
19632287-7	2009	Acute administration of harmine at the higher dose, but not imipramine, increased BDNF protein levels in the rat hippocampus.	Harmine	24-31	brain-derived neurotrophic factor	Rattus norvegicus	82-86
19586613-4	2009	This response does not require ERK1/2 or ERK5, but it is diminished by ablation of DYRK1A expression by siRNA or chemical inhibition of DYRK1A by harmine.	Harmine	146-153	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	83-89
19586613-4	2009	This response does not require ERK1/2 or ERK5, but it is diminished by ablation of DYRK1A expression by siRNA or chemical inhibition of DYRK1A by harmine.	Harmine	146-153	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	136-142
19796173-4	2009	Comparative in vitro assays of four kinases of the DYRK family showed that harmine inhibited substrate phosphorylation by DYRK1A more potently than it inhibited substrate phosphorylation by the closely related kinase DYRK1B [half maximal inhibitory concentrations (IC(50)) of 33 nm versus 166 nm, respectively] and by the more distant members of the family, DYRK2 and DYRK4 (1.9 microm and 80 microm, respectively).	Harmine	75-82	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	51-55
19796173-4	2009	Comparative in vitro assays of four kinases of the DYRK family showed that harmine inhibited substrate phosphorylation by DYRK1A more potently than it inhibited substrate phosphorylation by the closely related kinase DYRK1B [half maximal inhibitory concentrations (IC(50)) of 33 nm versus 166 nm, respectively] and by the more distant members of the family, DYRK2 and DYRK4 (1.9 microm and 80 microm, respectively).	Harmine	75-82	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	122-128
19796173-4	2009	Comparative in vitro assays of four kinases of the DYRK family showed that harmine inhibited substrate phosphorylation by DYRK1A more potently than it inhibited substrate phosphorylation by the closely related kinase DYRK1B [half maximal inhibitory concentrations (IC(50)) of 33 nm versus 166 nm, respectively] and by the more distant members of the family, DYRK2 and DYRK4 (1.9 microm and 80 microm, respectively).	Harmine	75-82	dual specificity tyrosine phosphorylation regulated kinase 1B	Homo sapiens	217-223
19796173-4	2009	Comparative in vitro assays of four kinases of the DYRK family showed that harmine inhibited substrate phosphorylation by DYRK1A more potently than it inhibited substrate phosphorylation by the closely related kinase DYRK1B [half maximal inhibitory concentrations (IC(50)) of 33 nm versus 166 nm, respectively] and by the more distant members of the family, DYRK2 and DYRK4 (1.9 microm and 80 microm, respectively).	Harmine	75-82	dual specificity tyrosine phosphorylation regulated kinase 2	Homo sapiens	358-363
19796173-4	2009	Comparative in vitro assays of four kinases of the DYRK family showed that harmine inhibited substrate phosphorylation by DYRK1A more potently than it inhibited substrate phosphorylation by the closely related kinase DYRK1B [half maximal inhibitory concentrations (IC(50)) of 33 nm versus 166 nm, respectively] and by the more distant members of the family, DYRK2 and DYRK4 (1.9 microm and 80 microm, respectively).	Harmine	75-82	dual specificity tyrosine phosphorylation regulated kinase 4	Homo sapiens	368-373
19796173-5	2009	Much higher concentrations of harmine were required to suppress tyrosine autophosphorylation of the translational intermediate of DYRK1A in a bacterial in vitro translation system (IC(50) = 1.9 microm).	Harmine	30-37	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	130-136
19796173-6	2009	Importantly, harmine inhibited the phosphorylation of a specific substrate by DYRK1A in cultured cells with a potency similar to that observed in vitro (IC(50) = 48 nm), without negative effects on the viability of the cells.	Harmine	13-20	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	78-84
19796173-9	2009	In summary, our data show that harmine inhibits DYRK1A substrate phosphorylation more potently than it inhibits tyrosine autophosphorylation, and provide evidence for a role of DYRK1A in the regulation of neurite formation.	Harmine	31-38	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	48-54
19796173-9	2009	In summary, our data show that harmine inhibits DYRK1A substrate phosphorylation more potently than it inhibits tyrosine autophosphorylation, and provide evidence for a role of DYRK1A in the regulation of neurite formation.	Harmine	31-38	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	177-183
19844572-7	2009	Moreover, these effects were abolished by treatment with harmine, the most potent and specific inhibitor of Dyrk1a.	Harmine	57-64	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	108-114
19372220-7	2009	Similarly, treatment of cardiomyocytes with harmine, a specific inhibitor of DYRK1A, revealed cardiomyocyte hypertrophy on morphological and molecular level.	Harmine	44-51	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	77-83